Drug-eluting systems and methods of use thereof

The 3D-printed biomaterial system addresses systemic toxicity and inefficiencies in drug delivery by providing localized, sustained release of therapeutic agents, enhancing treatment efficacy and reducing side effects.

WO2026236691A1PCT designated stage Publication Date: 2026-11-12BIOSAPIEN INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027411
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing drug delivery systems often result in systemic toxicity and inefficient localized delivery of therapeutic agents, particularly for chemotherapeutic agents, leading to undesirable side effects and the need for prolonged hospital administration.

Method used

A 3D-printed biomaterial system comprising polymers and active agents, designed for localized delivery at target sites, which minimizes systemic release and allows sustained drug elution over extended periods.

Benefits of technology

Enhances therapeutic efficacy by reducing systemic toxicity and side effects, enabling localized treatment with reduced healthcare costs and improved surgical outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027411_12112026_PF_FP_ABST
    Figure US2026027411_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure provides a method of treating or preventing a disease or condition. One or more delivery articles may be implanted into a subject. The delivery article of the one or more delivery articles may comprise a plurality of geometric elements. The delivery article may comprise a polymer and an active agent. When administered to a subject, the one or more delivery articles may deliver the active agent to a target tissue or region.
Need to check novelty before this filing date? Find Prior Art

Description

WSGR Docket No. 56745-707.601DRUG-ELUTING SYSTEMS AND METHODS OF USE THEREOF CROSS-REFERENCE

[0001] This application claims priority to and the benefit of U.S. Provisional Patent Application Serial No. 63 / 803,385, filed May 9, 2025, which is entirely incorporated herein by reference.BACKGROUND

[0002] Implantation of biomaterials can allow for the targeted delivery of a therapeutically-effective amount of a therapeutic agent. Targeted delivery of therapeutic agents can increase agent efficacy by increasing the exposure of target tissues to the agents and by mitigating systemic toxicity.SUMMARY

[0003] The present disclosure provides a drug delivery or drug elution system for targeted delivery of one or more drugs. In some embodiments, the system can deliver one or more drugs to a target site. In some embodiments, the system can deliver one or more drugs locally. In some embodiments, the system can deliver one or more drugs locally without significant release into systemic circulation.

[0004] In an aspect, the present disclosure provides a method of treating or preventing a disease or condition. The method comprises implanting into a subject one or more delivery articles. In some embodiments, a delivery article of the one or more delivery articles comprises a plurality of geometric elements. In some embodiments, the delivery article comprises a polymer and an active agent. In some embodiments, when administered to a subject, the one or more delivery articles deliver the active agent to a target tissue or region.

[0005] In another aspect, the present disclosure provides a method of preferentially delivering an active agent to a target tissue or region of a subject to treat or prevent a disease or condition. The method comprises implanting into the subject one or more delivery articles. In some embodiments, a delivery article of the one or more delivery articles comprises a plurality of geometric elements. In some embodiments, the delivery article comprises a polymer and an active agent. In some embodiments, a concentration of the active agent is higher in the target tissue or region than a non-targeted tissue or region.

[0006] In another aspect, the present disclosure provides a kit comprising a container comprising one or more delivery articles, and instructions for use.

[0007] Another aspect of the present disclosure provides a non-transitory computer readableWSGR Docket No. 56745-707.601

[0008] medium comprising machine executable code that, upon execution by one or more computer processors, implements any of the methods above or elsewhere herein.

[0009] Another aspect of the present disclosure provides a system comprising one or more computer processors and computer memory coupled thereto. The computer memory comprises machine executable code that, upon execution by the one or more computer processors, implements any of the methods above or elsewhere herein.

[0010] Additional aspects and advantages of the present disclosure will become readily apparent to those skilled in this art from the following detailed description, wherein only illustrative embodiments of the present disclosure are shown and described. As will be realized, the present disclosure is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, all without departing from the disclosure. Accordingly, the drawings and description are to be regarded as illustrative in nature, and not as restrictive.INCORPORATION BY REFERENCE

[0011] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and / or take precedence over any such contradictory material.BRIEF DESCRIPTION OF THE DRAWINGS

[0012] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also “Figure” and “FIG.” herein), of which:

[0013] FIG. 1A is a line drawing showing the architecture of an example implementation of a single layer of a biomaterial (or delivery article) of the disclosure. FIG. IB shows a schematic representation of the intra-article diffusion of an active agent (e.g., therapeutic agent) disclosed herein.

[0014] FIG. 2A and FIG. 2B show line drawings of a layer of a biomaterial (or delivery article) of the disclosure.WSGR Docket No. 56745-707.601

[0015] FIG. 3 shows a three-layered biomaterial comprising three layers of the single layer biomaterial (or delivery article) described in FIG. 1A.

[0016] FIG. 4A shows a photograph of an approximately 2 x 2 cm 3-D printed, PCL-based surgical mesh (or delivery article) of the disclosure. FIG. 4B shows a side view showing the thickness of the 2 x 2 cm 3-D-printed surgical mesh (or delivery article) of FIG. 4A.

[0017] FIG. 5 shows a release profile of 5 -fluorouracil (5-FU or 5FU) from a biomaterial (or delivery article) of the disclosure. Error bars represent standard deviation from three replicates.

[0018] FIG. 6 shows embodiments of the biomaterial (or delivery article), wherein the darker shading can refer to loading of one or more therapeutic agents (e.g., 5 -fluorouracil, gemcitabine).

[0019] FIG. 7 illustrates that a biomaterial (or delivery article) as disclosed herein can comprise a plurality of portions (e.g., north or N, south or S, west or W, east or E, etc.) capable of comprising drugs (e.g., 5 -fluorouracil, gemcitabine).

[0020] FIG. 8 provides a process flow diagram for making a biomaterial (or delivery article).

[0021] FIG. 9A is a computer-aided design (CAD) image of polymer-5FU biomaterial (or delivery article, chip). FIG. 9B shows a photograph of an example polymer-5FU biomaterial or chip.

[0022] FIG. 10 shows schematics of an example biomaterial that is inserted (Insertion), after 24 h of implantation (24 Hours), after 30 days of implantation (30 Days), and after removal from the subject (Removal).

[0023] FIG. 11 summarizes a process of making the biomaterial (or delivery article, chip).

[0024] FIG. 12 provides a packaging process for biomaterials (or delivery articles, chips).

[0025] FIG. 13 provides a making and quality control flow chart for a biomaterial (or delivery article, chip).

[0026] FIG. 14A provides a pictorial representation of the differences in plasma exposure observed for the 3 treated animals. FIG. 14B shows the 5-FU content in peritoneal wall. FIG.14C shows the 5-FU content in mesentery. FIG. 14D shows the 5-FU content in liver. FIG.14E shows the 5-FU content in colon. FIG. 14F shows a summary of the 5-FU content in different tissues.

[0027] FIG. 15A shows an image of an example tissue sample. FIG. 15B shows the locations the biomaterial (or delivery article, chip) was placed and was considered the colonimplant contact area. FIG. 15C shows the preserved epithelial barrier. FIG. 15D shows the suppurative inflammation and fibrin.WSGR Docket No. 56745-707.601

[0028] FIG. 16 shows the photomicrographs with Hematoxylin-Eosin (H&E) staining of healthy porcine tissue sample.

[0029] FIG. 17 shows a computer system 1801 that is programmed or otherwise configured to communicate with and regulate various aspects of the present disclosure.DETAILED DESCRIPTION

[0030] While various embodiments of the disclosure have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions may occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed.

[0031] As used herein, the singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. Any reference to “or” herein is intended to encompass “and / or” unless otherwise stated.

[0032] As used herein, “substantial” or “substantially” can refer to the complete or nearly complete extent or degree of an action, characteristic, property, state, structure, item, or result. The exact allowable degree of deviation from absolute completeness may in some cases depend on the specific context. The use of “substantial” or “substantially” is equally applicable when used in a negative connotation to refer to the complete or near complete lack of an action, characteristic, property, state, structure, item, or result.

[0033] As used herein, “effective amount” may refer to an amount of an ingredient or active agent which, when included in a composition, is sufficient to achieve an intended compositional or physiological effect. A “therapeutically effective amount” may refer to a substantially non-toxic, but sufficient amount of an active agent, to achieve therapeutic results in treating or preventing a condition for which the active agent is known to be effective. Various biological factors may affect the ability of an active agent to perform its intended task. Therefore, an “effective amount” or a “therapeutically effective amount” may be dependent in some instances on such biological factors. Individual variation and response to treatments may make the achievement of therapeutic effects a subjective decision.

[0034] The terms “active agent” and “therapeutic agent” may be used interchangeably herein.

[0035] As used herein, “subject” may refer to a mammal that may benefit from the administration of a composition or method as recited herein. Examples of subjects include humans, and can also include other animals such as horses, pigs, cattle, dogs, cats, rabbits, or aquatic mammals.WSGR Docket No. 56745-707.601

[0036] Whenever the term “at least,” “greater than,” or “greater than or equal to” precedes the first numerical value in a series of two or more numerical values, the term “at least,” “greater than” or “greater than or equal to” applies to each of the numerical values in that series of numerical values. For example, greater than or equal to 1, 2, or 3 is equivalent to greater than or equal to 1, greater than or equal to 2, or greater than or equal to 3.

[0037] Whenever the term “at most”, “no more than,” “up to,” “less than,” or “less than or equal to” precedes the first numerical value in a series of two or more numerical values, the term “no more than,” “less than,” or “less than or equal to” applies to each of the numerical values in that series of numerical values. For example, less than or equal to 3, 2, or 1 is equivalent to less than or equal to 3, less than or equal to 2, or less than or equal to 1.

[0038] The terms “biomaterial”, “delivery article”, “delivery vehicle”, and “chip” may be used interchangeably herein.

[0039] Targeted delivery systems for therapeutic agents can increase the efficacy of a therapeutic agent by, for example, increasing exposure of target tissues to the therapeutic agent, and by mitigating systemic toxicity. Targeted delivery can be desirable in the context of therapies that are highly toxic when administered systemically, and / or when administered over a prolonged period of time, such as chemotherapeutic agents and opioids.

[0040] The drug delivery or drug elution system disclosed herein offers a joint solution to the problems of surgery and chemotherapy and can be delivered in parallel with standard of care surgery. Innovations in component materials as well as the ultrastructure achieved through three-dimensional (3D) printing have resulted in a product prototype much more capable of stable release over long timescales than prior iterations. This innovation can allow desirable effects to be achieved with a single implantation. By localizing the effects of chemotherapy, the biomaterial offers an alternative to direct surgical resection in the delicate areas surrounding an area to be treated (e.g., the pancreas). Overall, sustained & localized release properties of the biomaterial can enhance both surgical and chemotherapeutic outcomes for patients. By reducing chemotherapy side effects and the need for in-hospital chemotherapy administration, healthcare costs can also be decreased.

[0041] In various aspects of the present disclosure, the delivery article (e.g., a biomaterial) disclosed herein can be used to deliver active agent (e.g., drugs) locally at the target site. In some cases, the target site may comprise a blood vessel, lymph nodes, cartilage, bone, liver, lungs, heart, pancreas, spleen, gastrointestinal tract, brain, pelvic, breast, and / or pulmonary tissue. In some cases, the target site may comprise deep tissue or connective tissues such as muscle and smooth muscles. In some cases, the target site may comprise a tumor site.WSGR Docket No. 56745-707.601

[0042] A biomaterial disclosed herein can be used to deliver drugs locally at the tumor site. This strategy aims to bypass the clinical side effects caused by the systemic toxicity of the chemotherapeutic drugs. The biomaterial can be organized with structures of pores and drug concentrated regions. This entropy of drug distribution can provide a key opportunity of regulating the drug release rate as desired and can be tailored to deliver a therapeutic dose for a particular disease indication. The biomaterial can be a pristine polymer and drug combination, e.g., without any additives or fillers reducing the likelihood of immune reactions or cross talking between various components. The polymer can have the drug dispersed in its matrix and deliver the drug in a slow and sustained manner. The release of the drug can be defined with a varied (e.g., optimized) combination of polymer and drug properties.

[0043] Advances in three-dimensional (3D) printing technologies can create new opportunities for producing customized delivery systems that can be adapted for a wide range of uses in the surgical theater. Three-dimensional printing can be advantageous due to the relatively low cost, simplicity, and versatility of a 3D printing system, as well as the high speed with which custom devices can be produced.

[0044] Disclosed herein is a biomaterial (or delivery article) that can serve as a surgical article and / or drug delivery system that can release a therapeutic agent directly to a target site over prolonged periods of time. The biomaterial can comprise one or more therapeutic agents that are loaded into a geometric element or a plurality of geometric elements of the article. Biomaterials, such as surgical articles, can be adapted for in situ sustained release of the one or more therapeutic agents. In some embodiments, the surgical articles are printed using an extrusion 3D printing method. Biomaterials can be custom printed in a shape and size suitable to cover a target site in situ. Biomaterials for implantation in situ can be in the general form of a surgical tape or mesh that can also be folded and / or layered. Suitable target sites include any site in the body of a subject requiring treatment with the one or more therapeutic agents. Non-limiting examples of target sites include tissues such as a blood vessel, lymph nodes, cartilage, ligament, bone, liver, lungs, heart, pancreas, spleen, gastrointestinal tract, brain, pelvic, breast, thorax, bladder, urinary tract, skin, peritoneum, ovarian, uterine, cervical, head and neck, ear, nose, throat, and pulmonary tissue. In some embodiments, a biomaterial can be applied to deep tissue and connective tissues such as muscle and smooth muscles. In some embodiments, upon selection of a target site within a subject’s body (e.g., upon application or implantation of a biomaterial to a particular target site, any other portion of the subject’s body may be a non-target site.WSGR Docket No. 56745-707.601

[0045] Biomaterials (or delivery articles) disclosed herein can comprise a polymer material, within at least a portion of which one or more active agents (e.g., therapeutic agents) can be dispersed. In some embodiments, the polymer material can also contain one or more additives. The polymer material can comprise or consist of one or more bioresorbable and / or biodegradable polymers, or a mixture of polymers including at least one bioresorbable and / or biodegradable polymer.

[0046] In some embodiments, the 3D printed surgical articles (or delivery articles, or biomaterials, as used interchangeably herein) are sterile, sterilizable, and / or sterilized before implantation into a subject.

[0047] In some embodiments, the polymer may be natural or synthetic in origin. In some embodiments, the polymer may be a homopolymer. In some embodiments, the polymer may be a copolymer derived from two or more monomers. In some embodiments, the one or more monomers utilized for the homopolymer or the copolymer may be caprolactone, lactide, glycolide, ethylene glycol, trimethylene carbonate, or combinations thereof. In some embodiments, the polymer may comprise a biocompatible polymer (e.g., causing no substantial interference with the functioning or physiology of the subject). In some embodiments, the polymer may comprise a biodegradable polymer. A biodegradable polymer can refer to a polymer that can erode or degrade (e.g., in vivo) under physiological conditions over time due, at least in part, to contact with substances found in the surrounding tissue fluids, or by cellular function. The release of the active agent can occur prior to, concurrent with, or subsequent to, the degradation of a biodegradable polymer over time.

[0048] In some embodiments, the biomaterial (or delivery article) may comprise a plurality of portions (or segments or compartments), e.g., at least or at most about 2 portions, at least or at most about 3 portions, at least or at most about 4 portions, at least or at most about 5 portions, at least or at most about 6 portions, at least or at most about 7 portions, at least or at most about 8 portions, at least or at most about 9 portions, at least or at most about 10 portions, etc. In some embodiments, two or more of the plurality of portions may be the same or different. In some embodiments, two or more of the plurality of portions may have the same polymer or different polymers. In some embodiments, two or more of the plurality of portions may comprise the same active agent or different active agents.

[0049] Descriptions of a first portion and a second portion of the plurality of portions, as provided herein, may be applicable to other portions of the biomaterial where applicable.

[0050] In some embodiments, the biomaterial may comprise a first portion and a second portion. In some embodiments, the first portion may comprise a first polymer. In someWSGR Docket No. 56745-707.601embodiments, the first portion may comprise a first active agent. In some embodiments, the second portion may comprise a second polymer. In some embodiments, the second portion may comprise a second active agent. Alternatively, the second portion may not comprise any active agent. In some embodiments, the first polymer, the second polymer, or both may comprise a homopolymer. In some cases, the first polymer, the second polymer, or both may comprise a copolymer. In some embodiments, the first polymer, the second polymer, or both may comprise a heterogeneous mixture of polymers.

[0051] In some embodiments, the first polymer, the second polymer, or both may comprise a mixture of polymers of the same type or of different types. In some embodiments, the copolymer may comprise one or more of a block copolymer (e.g., diblock copolymer, triblock copolymer, or multiblock copolymer, alternating copolymer, statistical or random copolymer, a star copolymer, a brush copolymer, a gradient copolymer, or a graft copolymer. In some embodiments, the first polymer, the second polymer, or both may comprise polycaprolactone (PCL), poly-(D-lactic acid) (PDLA), poly-(L-lactic acid) (PLLA), poly(D,L-lactic acid) (PLA), poly(L-lactide-co-caprolactone), poly(D-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone), polyvinyl alcohol (PVA), polyethylene glycol) (PEG), poly(glycolic acid) (PGA), poly(L-lactide-co-glycolide), poly(D-lactide-co-glycolide), poly(D,L-lactide-co-glycolide) (PLGA), polyethylene glycol diacrylate (PEGDA), poly(L-lactide-co-trimethylene carbonate), poly(D-lactide-co-trimethylene carbonate), poly(D,L-lactide-co-trimethylene carbonate), poly(trimethylene carbonate-co-caprolactone), poly(caprolactone-co-glycolide), polyorthoesters, polyanhydrides, polyesters, polyamides, polyesteramides, polycarbonates, polyethylene, polypropylene, polygalactic acid, polyacrylamide, polystyrene, polyurethane, silicone, hydroxypropylmethylcellulose, hydroxypropylcellulose, polyglycolic acid-polyvinyl alcohol copolymers, polycaprolactonepolyethylene glycol copolymers, collagen, croscarmellose collagen, hyaluronic acid, elastin, polyhydroxybutyrate, polyalkaneanhydrides, gelatin, cellulose, oxidized cellulose, polyphosphazene, poly(sebacic acid), poly(ricenolic acid), poly(fumaric acid), chitin, chitosan, polyvinylpyrrolidone, synthetic cellulose esters, polyacrylic acids, polybutyric acid, poly(N-isopropylacrylamide), poly(ethylene oxide-co-propylene oxide-co-ethylene oxide), poly(valeric acid), poly(valerolactone), polyhydroxyalkylcellulose, polysiloxane, poly(dimethylsiloxane-co-methylvinylsiloxane), poly(dimethylsiloxane-co-methylvinylsiloxane-co-methylhydrogensiloxane), polypeptides, poly(amino acids), poly(dioxanones), poly(alkylene alkylates), hydrophobic polyethers, polyetheresters, polyacetals, polycyanoacrylates, poly acrylates, polymethylmethacrylates, polysiloxanes,WSGR Docket No. 56745-707.601poly(oxyethylene-co-oxypropylene), polyketals, polyphosphates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(maleic acid), polycaprolactone dimethacrylate, polycaprolactone methacrylate or a derivative thereof, or a copolymer thereof, or combination thereof. In some cases, the first polymer, the second polymer, or both may be cross-linked. In some cases, the first polymer, the second polymer, or both may be non-cross-linked. In some cases, the first polymer, the second polymer, or both can comprise polycaprolactone. In some cases, the first polymer, the second polymer, or both can comprise polylactic acid. In some cases, the first polymer can comprise poly(lactide-co-caprolactone). In some cases, the first polymer, the second polymer, or both can comprise poly(L-lactide-co-caprolactone). In some cases, the first polymer, the second polymer, or both can comprise a mixture of polymers disclosed herein.

[0052] In some embodiments, the first portion may comprise a first geometric element comprising a border and / or a solid region. In some embodiments, the second portion may comprise a second geometric element comprising a border and / or a solid region. In some embodiments, the first geometric element, the second geometric element, or both may be characterized by having a degree of porosity as provided herein. In some embodiments, a cross-sectional shape of the first geometric element, the second geometric element, or both may comprise a shape of triangle, rectangle, square, diamond, pentagon, hexagon, octagon, polygon, circle, or oval. In some cases, the first portion may be porous, non -porous, or semi-porous. In some embodiments, the first geometric element, the second geometric element, or both may be two-dimensional (2D) or three-dimensional (3D).

[0053] In some embodiments, the biomaterial may comprise a first portion comprising a first polymer and a first active agent. The biomaterial may comprise a second portion comprising a second polymer and a second active agent. In some cases, the first portion may be enclosed or surrounded by a first perimeter. In some cases, the first perimeter may comprise a third polymer. In some cases, the first perimeter may be substantially impermeable. In some cases, the first perimeter may be substantially free of an active agent. In some cases, the first perimeter may be non-porous, porous, or semi-porous. In some cases, the third polymer may comprise any suitable polymer as disclosed herein. In some cases, the second portion may be enclosed or surrounded by a second perimeter. In some cases, the second perimeter may comprise a fourth polymer. In some cases, the second perimeter may be substantially impermeable. In some cases, the second perimeter may be substantially free of an active agent. In some cases, the second perimeter may be non-porous, porous, or semi-porous. In some cases, the fourth polymer may comprise any suitable polymer as disclosed herein.WSGR Docket No. 56745-707.601

[0054] In some embodiments, the first portion may comprise an amount of the first polymer of at least about 10 milligrams (mg), at least about 20 mg, at least about 30 mg, at least about 40 mg, at least about 50 mg, at least about 60 mg, at least about 70 mg, at least about 80 mg, at least about 90 mg, or at least about 100 mg. In some cases, the first portion may comprise an amount of the first polymer of at most about 100 mg, at most about 90 mg, at most about 80 mg, at most about 70 mg, at most about 60 mg, at most about 50 mg, at most about 40 mg, at most about 30 mg, at most about 20 mg, or at most about 10 mg. In some embodiments, the second portion may comprise an amount of the second polymer of at least about 10 mg, at least about 20 mg, at least about 30 mg, at least about 40 mg, at least about 50 mg, at least about 60 mg, at least about 70 mg, at least about 80 mg, at least about 90 mg, or at least about 100 mg. In some cases, the second portion may comprise an amount of the second polymer of at most about 100 mg, at most about 90 mg, at most about 80 mg, at most about 70 mg, at most about 60 mg, at most about 50 mg, at most about 40 mg, at most about 30 mg, at most about 20 mg, or at most about 10 mg.

[0055] In some embodiments, the amount of the active agent in the respective portion of the biomaterial (e.g., the first active agent in the first portion or the second active agent in the second portion) may be at least about 50 micrograms (pg), at least about 60 pg, at least about 70 pg, at least about 80 pg, at least about 90 pg, at least about 100 pg, at least about 150 pg, at least about 200 pg, at least about 250 pg, at least about 300 pg, at least about 350 pg, at least about 400 pg, at least about 450 pg, at least about 500 pg, at least about 600 pg, at least about 650 pg, at least about 700 pg, at least about 750 pg, at least about 800 pg, at least about 850 pg, at least about 900 pg, at least about 1 mg, at least about 2 mg, at least about 3 mg, at least about 4 mg, at least about 5 mg, at least about 10 mg, at least about 15 mg, at least about 20 mg, at least about 25 mg, at least about 30 mg, at least about 35 mg, or at least about 40 mg; and / or at most about 40 mg, at most about 35 mg, at most about 30 mg, at most about 25 mg, at most about 20 mg, at most about 15 mg, at most about 10 mg, at most about 5 mg, at most about 4 mg, at most about 3 mg, at most about 2 mg, at most about 1 mg, at most about 900 pg, at most about 850 pg, at most about 800 pg, at most about 750 pg, at most about 700 pg, at most about 650 pg, at most about 600 pg, at most about 500 pg, at most about 400 pg, at most about 300 pg, at most about 200 pg, at most about 100 pg, at most about 90 pg, at most about 80 pg, at most about 70 pg, at most about 60 pg, or at most about 50 pg.

[0056] In some embodiments, the amount of the polymer in the respective portion of the biomaterial (e.g., the first polymer in the first portion or the second polymer in the secondWSGR Docket No. 56745-707.601portion) may be at least about 1 milligram (mg), at least about 2 mg, at least about 3 mg, at least about 4 mg, at least about 5 mg, at least about 10 mg, at least about 15 mg, at least about 20 mg, at least about 25 mg, at least about 30 mg, at least about 35 mg, or at least about 40 mg; and / or at most about 40 mg, at most about 35 mg, at most about 30 mg, at most about 25 mg, at most about 20 mg, at most about 15 mg, at most about 10 mg, at most about 5 mg, at most about 4 mg, at most about 3 mg, at most about 2 mg, or at most about 1 mg.

[0057] In some embodiments, the biomaterial may comprise a weight of at least about 100 mg, at least about 120 mg, at least about 140 mg, at least about 160 mg, at least about 180 mg, at least about 200 mg, at least about 300 mg, or at least about 400 mg; and / or at most about 400 mg, at most about 300 mg, at most about 200 mg, at most about 180 mg, at most about 160 mg, at most about 140 mg, at most about 120 mg, or at most about 100 mg.

[0058] In some embodiments, the biomaterial may comprise a dimension (e.g., length, width, diameter, etc.) of at least about 0.1 cm, at least about 0.2 cm, at least about 0.4 cm, at least about 0.6 cm, at least about 0.8 cm, at least about 1 cm, at least about 2 cm, at least about 3 cm, at least about 4 cm, at least about 5 cm, at least about 6 cm, at least about 7 cm, at least about 8 cm, at least about 9 cm, at least about 10 cm, at least about 12 cm, at least about 14 cm, at least about 15 cm, or at least about 20 cm; and / or at most about 20 cm, at most about 15 cm, at most about 14 cm, at most about 12 cm, at most about 10 cm, at most about 5 cm, at most about 2 cm, at most about 1 cm, at most about 0.8 cm, at most about 0.6 cm, at most about 0.4 cm, at most about 0.2 cm, or at most about 0.1 cm.

[0059] In some embodiments, the biomaterial may comprise a thickness of at least about 0.01 millimeters (mm), at least about 0.1 mm, at least about 0.5 mm, at least about 1 mm, at least about 2 mm, at least about 3 mm, at least about 4 mm, at least about 5 mm, at least about 6 mm, at least about 7 mm, at least about 8 mm, at least about 9 mm, at least about 10 mm, at least about 12 mm, at least about 14 mm, at least about 15 mm, at least about 20 mm; and / or at most about 20 mm, at most about 15 mm, at most about 14 mm, at most about 12 mm, at most about 10 mm, at most about 5 mm, at most about 2 mm, at most about 1 mm, at most about 0.5 mm, or at most about 0.1 mm.

[0060] In some embodiments, one or more biomaterials as provided herein may be introduced or implanted to achieve an effective amount (e.g., an effective amount of therapeutic agent carried by the biomaterial(s)). In some embodiments, at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, or at least about 10, or more biomaterials can be introduced or implanted. In some cases, at most about 10, at most about 9, at most about 8, atWSGR Docket No. 56745-707.601most about 7, at most about 6, at most about 5, at most about 4, at most about 3, at most about 2, or at most about 1 biomaterial(s) can be introduced or implanted.

[0061] In some embodiments, the biomaterial may be flexible. In some embodiments, the biomaterial may not be flexible.

[0062] In some embodiments, the biomaterial may exhibit a mechanical property (e.g., a Young’s modulus or a modulus of elasticity) that is substantially similar to (e.g., different by no more than 20%, no more than 15%, no more than 10%, no more than 5%, no more than 2%, no more than 1%, or less) or matches that a biological tissue as provided herein. Such biomaterial may reduce irritation and maintain structural integrity of the tissue. In some embodiments, the biomaterial may be able to contour to shape of a tissue or tumor surface when implanted. In some embodiments, the biomateiral may comprise a Young’s modulus from about 0.1 kilopascal (kPa) to about 10 megapascal (MPa), from about 0.1 kPa to about 0.5 kPa, from about 0.1 kPa to about 1 kPa, from about 0.1 kPa to about 5 kPa, from about 0.1 kPa to about 10 kPa, from about 0.5 kPa to about 2 kPa, from about 0.5 kPa to about 5 kPa, from about 1 kPa to about 5 kPa, from about 1 kPa to about 10 kPa, from about 1 kPa to about 50 kPa, from about 1 kPa to about 100 kPa, from about 2 kPa to about 20 kPa, from about 5 kPa to about 50 kPa, from about 5 kPa to about 100 kPa, from about 5 kPa to about 500 kPa, from about 10 kPa to about 100 kPa, from about 10 kPa to about 500 kPa, from about 10 kPa to about 1 MPa, from about 50 kPa to about 500 kPa, from about 50 kPa to about 1 MPa, from about 100 kPa to about 1 MPa, from about 100 kPa to about 5 MPa, from about 100 kPa to about 10 MPa, from about 500 kPa to about 5 MPa, from about 500 kPa to about 10 MPa, from about 1 MPa to about 10 MPa, etc. Alternatively, the mechanical property of the biomaterial may not and need not match that of a biological tissue (e.g., a target site where the biomaterial may be implanted to).

[0063] In some embodiments, the biomaterial as provided herein may deliver one or more active agents locally at, near, or adjacent to the site the biomaterial is administered at (e.g., implanted at). In some embodiments, the biomaterial as provided herein may not result in a significant amount of the active agent entering systemic circulation (e.g., in the blood vessel or plasma, in the liver, etc.), e.g., due at least in part to localized release of the biomaterial.

[0064] A biomaterial disclosed herein can be biocompatible. A biocompatible biomaterial can be administered or implanted into the body of a subject without undesirable effects such as, for example, an immune and / or inflammatory reaction.

[0065] A biomaterial disclosed herein can be biodegradable. A biodegradable biomaterial can degrade (partially or completely) under physiological conditions into non-toxic products thatWSGR Docket No. 56745-707.601can be metabolized or excreted from the body. In some instances, biodegradable materials are degraded by enzymatic activity, for example by enzymatic hydrolysis.

[0066] In some embodiments, a biomaterial of the disclosure is bioresorbable or bioabsorbable. Bioresorbable or bioabsorbable materials can be broken down and absorbed by cells and / or tissues.

[0067] In some embodiments, a biomaterial described herein is configured to resorb and / or degrade after placement in situ over a period of time ranging from about 1 day to about 1 week, about 1 week to about 1 month, 1 month to about 3 months, about 3 months to about 6 months, about 6 months to about 12 months, about 12 months to about 24 months, or from about 2 years to about 5 years. The resorption and / or degradation time can be modulated by controlling the composition of the polymer material, including the types of polymers and porosity of the material, as well as by the two- and three-dimensional arrangement of geometric elements and comprising the article.

[0068] A biomaterial (e.g., surgical article or delivery article) as described here can comprise one geometric element or a plurality of geometric elements. In some embodiments, the geometric elements of a plurality of geometric elements are in fluid communication with each other. In some embodiments, a plurality of geometric elements is printed on an x-y plan, for example as a ribbon, grid, or other shape to form a biomaterial of a desired shape and / or size. In some embodiments, a plurality of geometric elements can be printed vertically, on top of one another. In some embodiments, a thickness of a single layer article can be in the range of about 0.01 mm to about 0.1 cm, about 0.25 mm to about 1 cm, about 0.5 mm to about 1 cm, about 0.75 mm to about 1 cm, about 0.1 mm to about 2 cm, about 0.25 mm to about 2 cm, about 0.5 mm to about 2 cm, about 0.75 mm to about 2 cm, about 0.1 mm to about 3 cm, about 0.25 mm to about 3 cm, about 0.5 mm to about 3 cm, about 0.75 mm to about 3 cm, about 0.1 mm to about 4 cm, about 0.25 mm to about 4 cm, about 0.5 mm to about 4 cm, about 0.75 mm to about 4 cm, about 0.1 mm to about 5 cm, about 0.25 mm to about 5 cm, about 0.5 mm to about 5 cm, or about 0.75 mm to about 5 cm.

[0069] In some embodiments, a biomaterial of the disclosure may comprise multiple layers, wherein each layer may comprise a plurality of geometric elements. For example, a biomaterial of the disclosure can comprise at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or more layers; and / or at most 10, at most 9, at most 8, at most 7, at most 6, at most 5, at most 4, at most 3, at most 2, or at most 1 layer. In some embodiments, each layer of a biomaterial is oriented such that the layer is offset from the unit above and / or below, for example at a defined angle such as, for example, aboutWSGR Docket No. 56745-707.60115 degrees, about 30 degrees, about 45 degrees, about 60 degrees, about 90 degrees, about 105 degrees, about 120 degrees, about 135 degrees, about 150 degrees, about 165 degrees, or about 180 degrees. The defined angle may be at least about 15 degrees (°), at least about 30°, at least about 45°, at least about 60°, at least about 90°, at least about 105°, at least about 120°, at least about 135°, at least about 150°, at least about 165°, at least about 180°; and / or at most about 180°, at most about 165°, at most about 150°, at most about 135°, at most about 120°, at most about 105°, at most about 90°, at most about 60°, at most about 45°, at most about 30°, or at most about 15°.

[0070] The overall dimensions of a biomaterial of the disclosure can be adapted to accommodate a wide range of in situ target sites. In accordance with any of these embodiments, one or more geometric elements of a plurality of geometric elements can be printed with or without one or more therapeutic agents. A biomaterial of the disclosure can have any shape. For example, the overall shape of a surgical article in accordance with the present description can be circular, oval, rectangular, triangular, octangular, pentangular, hexangular, heptangular, or square, and the size can be adapted to cover an area in the range of, for example, from about 4 cm2to about 200 cm2. In some embodiments, the article is of a size suitable to cover an area of from about 20 cm2to about 50 cm2, from about 50 cm2to about 100 cm2, or from about 100 cm2to about 200 cm2. In some embodiments, the article can range in size from about 0.25 cm x 0.25 cm, 0.5 cm x 0.5 cm, 1 cm x 1 cm, 1.5 cm x 1.5 cm, 2 cm x about 2 cm up to about 12 cm x about 10 cm. For example, a biomaterial of the disclosure can be a 2 cm x 2 cm, 4 cm x 4 cm, 6 cm x 6 cm, or 8 cm x 8 cm square article, or 4 cm x 6 cm, 8 cm x 6 cm, 10 cm x 8 cm, or 12 cm x 10 cm rectangular article. The delivery article can be used in multiples like the Lego system of attaching one to another and covering much larger surface area than mentioned.

[0071] In some embodiments, a biomaterial of the disclosure (e.g. a surgical article or delivery article as used interchangeably) can further comprise a loop or similar feature configured to facilitate the placement of the biomaterial in situ, for example by suturing.

[0072] A biomaterial disclosed herein can have a flexible structure. The biomaterial can be a dosage form that is locally administered using a minimally invasive / endoscopic procedure. The biomaterial can allow an active agent (e.g., 5-FU) to directly target cells at hard-to-reach target site (e.g., target tumor cells at hard to reach tumor sites). This site-specific delivery technology can reduce side effects caused by systemic therapy. The biomaterial can downsize localized tumors, alleviate local symptoms, and potentially prevent or reduce the likelihood of life-altering surgeries such as colostomy.WSGR Docket No. 56745-707.601

[0073] In some embodiments a biomaterial disclosed herein is radiopaque. In some embodiments a biomaterial disclosed herein contains no or substantially no additives or fillers other than a drug and excipient (e.g., PCL) disclosed herein. In some embodiments, a biomaterial releases an active pharmaceutical ingredient (API) from pores within the biodegradable polymer in a slow-release (e.g., biphasic release) manner over a period, e.g., for at least about 72 hours, 1 week, 2 weeks, at least about 4 weeks, at least about 1 month, at least about 2 month, at least about 4 month, at least about 5 month, at least about 10 month, at least about 15 month, at least about 20 month, at least about 25 month, at least about 30 month, or at least about 36 month. The release can be enhanced by the hydrophobicity of the product polymer.

[0074] In another aspect, the present disclosure provides a kit. The kit may comprise a container comprising one or more delivery articles as disclosed herein. The delivery article may comprise a material (e.g., a biocompatible matrix). In some cases, the kit can comprise instructions for use.

[0075] The kit may comprise one or more elements disclosed herein in relation to any of the various aspects, in any combination. Materials in a kit may be contained in any suitable container and may be in an immediately usable form or require combination with other materials in the kit or materials supplied by a user. The kit may provide one or more tools for handling one or more delivery articles disclosed herein. In some cases, the kit may further comprise another container comprising one or more tools configured to implant a delivery article to a subject.Structure of geometric elements

[0076] A biomaterial of the disclosure can comprise a plurality of geometric elements.Geometric elements of a plurality of geometric elements can be adjacent and / or in fluidic communication with one another. In some embodiments, the geometric elements form a layer. Geometric elements can be formed by a border comprising a polymer. In some embodiments, a border of a geometric element can further comprise one or more therapeutic agents disclosed herein. A border forming a geometric element can be porous, non-porous, or minimally porous. A porous border can allow for the diffusion of a therapeutic agent through the border and into or out of the geometric element formed by the border. In some embodiments, a border is minimally porous such that a therapeutic agent cannot diffuse through the border and into the geometric element formed by the border.WSGR Docket No. 56745-707.601

[0077] A geometric element formed by a border can comprise, for example, an empty space or a solid region within the border. A solid region of a geometric element can be porous, non-porous, or minimally porous. A porous solid region can allow for the diffusion of a therapeutic agent through the solid region and into or out of a geometric element. In some embodiments, a solid region is minimally porous such that a therapeutic agent cannot diffuse through the solid region and into the geometric element formed by the border.

[0078] A border and / or solid region of a geometric element can have a degree of porosity. In some embodiments, the degree of porosity of a border or solid region is about 10% to about 99%. In some embodiments, the degree of porosity of a border or solid region is about 10% to about 20%, about 10% to about 30%, about 10% to about 40%, about 10% to about 50%, about 10% to about 60%, about 10% to about 70%, about 10% to about 80%, about 10% to about 90%, about 10% to about 99%, about 20% to about 30%, about 20% to about 40%, about 20% to about 50%, about 20% to about 60%, about 20% to about 70%, about 20% to about 80%, about 20% to about 90%, about 20% to about 99%, about 30% to about 40%, about 30% to about 50%, about 30% to about 60%, about 30% to about 70%, about 30% to about 80%, about 30% to about 90%, about 30% to about 99%, about 40% to about 50%, about 40% to about 60%, about 40% to about 70%, about 40% to about 80%, about 40% to about 90%, about 40% to about 99%, about 50% to about 60%, about 50% to about 70%, about 50% to about 80%, about 50% to about 90%, about 50% to about 99%, about 60% to about 70%, about 60% to about 80%, about 60% to about 90%, about 60% to about 99%, about 70% to about 80%, about 70% to about 90%, about 70% to about 99%, about 80% to about 90%, about 80% to about 99%, or about 90% to about 99%. In some embodiments, the degree of porosity of a border or solid region is about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 99%. In some embodiments, the degree of porosity of a border or solid region is at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%. In some embodiments, the degree of porosity of a border or solid region is at most about 20%, at most about 30%, at most about 40%, at most about 50%, at most about 60%, at most about 70%, at most about 80%, at most about 90%, or at most about 99%.

[0079] The porosity of borders and / or solid regions can vary throughout a biomaterial of the disclosure. In some embodiments, a porous border surrounds a solid region that is minimally porous or non-porous. In some embodiments, a minimally porous or non-porous border surrounds a solid region that is porous. In some embodiments, a non-porous or minimallyWSGR Docket No. 56745-707.601porous border surrounds a solid region that is non-porous or minimally porous. In some embodiments, a porous border surrounds a porous solid region.

[0080] Adjacent geometric elements can share an edge, and thus form a portion of the border forming the geometric elements. In some embodiments, adjacent elements each comprise distinct edges / borders that are adjacent to and / or in contact with one another.

[0081] Borders can form geometric elements of any shape. For example, a border can form a geometric element that is circular, elliptical, triangular, rectangular, pentangular, hexangular, heptangular, octangular, or irregularly shaped. In some embodiments, a border forms a geometric element that is a nonagon or decagon. Geometric elements of a plurality of geometric elements can be the same or different geometric elements. In some embodiments, a biomaterial or layer thereof can comprise a plurality of geometric elements defining two or more hexagons, triangles, and diamonds, or portions thereof. In some embodiments, the length of the edges of a particular element ranges from 1.0 mm to 10 mm, or from 1.0 mm to 5 mm, or from 1.0 mm to 3 mm. Depending on the geometric shape defined by the edges of the element, the edges can be the same or different lengths. In some embodiments, each edge of a geometric element is uniform in length and / or width.

[0082] In some embodiment, a biomaterial disclosed herein is comprised of a plurality of layers, each layer formed from a plurality of open and filled geometric elements forming a defined pattern. The plurality of geometric elements can comprise elements having three, four, five, or six edges. In some embodiments, the edges of the elements can define one or more geometric elements selected from triangles, diamonds, hexagons, and portions of any of the foregoing. In some embodiments, the triangles are equilateral triangles and the edges of each geometric element are of uniform length. In some embodiments, the edges have a length of from about 1 to about 3 mm, from about 1 to about 2 mm, for example about 1.0 mm, about 1.5 mm, about 2.0 mm, about 2.5 mm, or about 3.0 mm.

[0083] One or more therapeutic agents can be loaded into geometric elements. For example, one or more geometric agents can be dispersed within a solid region or a border of a one or more geometric elements of a biomaterial of the disclosure.Arrangement of geometric elements

[0084] In some embodiments, a plurality of geometric elements forming a biomaterial or layer thereof here is arranged in a defined pattern of elements comprising solid regions (i.e., filled elements) and empty spaces (i.e., open elements), the pattern adapted to modulate release of the therapeutic agent(s) from the drug reservoir element(s) of the unit article in situ.WSGR Docket No. 56745-707.601For example, the size and shape of the elements forming the biomaterial or layer thereof can be increased or decreased to modulate the surface area of the filled elements and the pore size of the open elements, in order to modulate the release of the therapeutic agent or agents from the article. The volume and number of therapeutic-agent loaded element(s) can determine the amount of the therapeutic agent(s) in the unit article and the amount released in situ at the target site. The volume of the therapeutic-agent loaded element(s) can be increased, for example, by printing multiple single layers of biomaterial on top of each other until a desired thickness is reached, thereby allowing a higher loading volume for the therapeutic agent(s). The defined pattern of open and filled geometric elements can further be used to modulate the total surface area of the unit article, as well as the surface area of the unit article from which a therapeutic agent(s) is released.Release of therapeutic agents

[0085] Release of one or more therapeutic agents into a target site in situ from a biomaterial of the disclosure can occur from the exposed surface(s) of the biomaterial. Additionally, or alternatively, one or more therapeutic agents can diffuse within a biomaterial disclosed herein.

[0086] For example, in some embodiments, a defined pattern of open and filled geometric elements with porous and / or non-porous components (e.g. borders or solid regions) can be used to direct or focus any intra-biomaterial diffusion of a therapeutic agent to a defined region of the biomaterial. Focusing diffusion of a therapeutic agent can have the effect of a more concentrated release of a therapeutic agent from a region of a biomaterial. Thus, depending on the type of therapy, duration of treatment, and the location of an in situ target site, the amount and rate of release of therapeutic agent(s) from a biomaterial described herein can be controlled through a combination of the defined pattern of open and filled geometric elements forming the biomaterial, the inclusion of one or more additives, such as a poragen, and the amount of the agent(s) loaded into the geometric elements of the biomaterial.

[0087] In some embodiments, release of a therapeutic agent from a biomaterial disclosed herein can be modulated by increasing the thickness of the biomaterial (e.g. by using multiple layers and / or by sequestering the geometric element(s) loaded with therapeutic agent within internal layers of a folded biomaterial or a stack of biomaterials or layers thereof. Folding and stacking of the biomaterials of layers thereof in this manner can reduce the surface area from which a therapeutic agent can be released. In some embodiments, a surgical article can beWSGR Docket No. 56745-707.601formed from alternating layers of unit articles in a stacked configuration where the alternating layers are staggered or slanted, for example at about 180 degrees, about 90 degrees or about 45 degrees. For example, in the staggered configuration, two or more layers of a biomaterial are layered horizontally on top of one another at a 180 degree, 90 degree, or 45 degree angle. In some embodiments, the thickness of a folded or stacked article can range from about 0.5 cm to about 3 cm. In some embodiments, the thickness of the folded or stacked article may be at least about 0.1 mm, at least about 0.5 mm, at least about 1 mm, at least about 5 mm, at least about 1 cm, at least about 1.5 cm, at least about 2 cm, at least about 2.5 cm, at least about 3 cm, or at least about 4 cm; and / or at most about 4 cm, at most about 3 cm, at most about 2.5 cm, at most about 2 cm, at most about 1.5 cm, at most about 1 cm, at most about 5 mm, or at most about 1 mm.

[0088] In some embodiments, one or more therapeutic agents can be coated onto the surface of a biomaterial in addition to, or instead of, being dispersed within the polymer material of the biomaterial.

[0089] In some embodiments, the biomaterial as provided herein may be functional (e.g., may exhibit localized release of the loaded active ingredient to the surrounding environment) in different conditions including, but not limited to, various temperatures (e.g., different ranges of temperatures around body temperature, room temperature, or both), various pH values (e.g., from pH 1 to pH 10), various oxygen levels (e.g., from 0 to 5 mmHg, from 5 to 40 mmHg, etc.), various hydration levels, various immune environment, various enzymatic environment, and / or in or adjacent to different medium (e.g., water, blood, plasma, etc.). For example, in the colon, the biomaterial may encounter pH ranges from 5.5 to 7.5 in the lumen and from 6.5 to 7.4 in surrounding tissue, with oxygen levels ranging from near anaerobic (e.g., from 0 to 5 mmHg) in the lumen to from 5 to 40 mmHg in tissue, all within a highly hydrated environment, and such biomaterial may be functional therein. In another example, in the flank (e.g., a subcutaneous tissue), the biomaterial may experience relatively stable conditions with pH ranging from 7.2 to 7.4, oxygen levels from 20 to 60 mmHg (e.g., dropping to a range from 5 to 20 mmHg locally), and a highly hydrated environment (e.g., from 70% to 80% water), and such biomaterial may be functional therein. In some embodiments, the biomaterial may be functional or operable in a pH range from pH 1 to pH 10, from pH 1 to pH 9, from pH 1 to pH 8, from pH 2 to pH 10, from pH 2 to pH 9, from pH 2 to pH 8, from pH 3 to pH 10, from pH 3 to pH 9, from pH 3 to pH 8, or from pH 4 to pH 10. In some embodiments, the biomaterial may be functional or operable in various oxygen levels.WSGR Docket No. 56745-707.601Biomaterial structure

[0090] A schematic of a non-limiting example of a biomaterial of the disclosure is shown in FIG. 1A. As shown in FIG. 1A, a biomaterial (or delivery article as used interchangeably herein) of the disclosure (100) can comprise twenty-seven open (i.e. filled with empty space) or filled elements defining five different geometric elements and portions thereof. Two filled triangular elements (101) and seven filled diamond shaped elements (102) can be positioned to modulate diffusion of a therapeutic agent infused within portions of the biomaterial, including within adjacent filled hexagonal elements (103). In some embodiments, the filled elements each contain the same polymer or mixtures of polymers. The filled elements can contain polymers or mixtures of polymers with the same or different porosities. For example, some of the filled elements can function as a barrier to intra-material diffusion of the therapeutic agent, while other filled elements can contain pores that serve to allow intramaterial diffusion of the therapeutic agent into the area defined by the porous filled elements. The degree of porosity of polymers making up the biomaterial can be modulated by the manufacturing process.

[0091] In FIG. 1A, the filled triangular elements (101) are formed by a non-porous border (109) around an essentially non-porous solid region. The filled triangular elements (109) can serve to focus the intra-material diffusion of the therapeutic agent into adjacent regions defined by porous or open elements, for example the filled hexagonal elements (103), the open hexagonal elements, (105), and / or the open triangular elements and portions thereof (104). The focusing of the intra-material diffusion can, for example, target release of a therapeutic agent toward a defined region of the biomaterial for release in a more concentrated fashion at a particular region within a target site in situ.

[0092] As shown in FIG. 1A, a biomaterial disclosed herein can comprise four filled hexagonal elements (103) formed by a porous border (108) and a solid region, each comprising polymer and the therapeutic agent dispersed within the polymer. The biomaterial can further comprise two filled diamond-shaped elements (106) formed by a solid region and a porous border, each comprising polymer and the therapeutic agent dispersed within the polymer. In some embodiments, the porous border may be formed by the edges of the solid region. Throughout the biomaterial, the border of a geometric element with a solid region can have a composition that may be the same or different than the composition of the solid region. In some embodiments, a biomaterial contains diamond-shaped filled elements (102) formed by a porous border and a porous solid region that is not infused with therapeutic agent, but which allows for intra-material diffusion of the therapeutic agent into theseWSGR Docket No. 56745-707.601diamond-shaped filled elements (102). Diffusion of the therapeutic agent into the non-therapeutic agent infused diamond-shaped elements (102) increases the surface area from which the therapeutic agent diffuses into the in situ target site.

[0093] A biomaterial disclosed herein can further comprise a plurality of filled and open elements that serve to increase the overall surface area of the biomaterial, impart structural integrity to the biomaterial, impart flexibility to the bio biomaterial, and / or serve as optional fixation points on the biomaterial. For example, as shown in FIG. 1A, open elements (104, 105) of a biomaterial disclosed herein can serve as fixation points to suture the biomaterial in place at a target site. The borders (107) forming the open elements (104, 105) can be porous or nonporous borders. In some embodiments the borders forming the open elements (104, 105) of a biomaterial disclosed herein comprise a polymer and a therapeutic agent (e.g. 5-fluorouracil) infused within the polymer.

[0094] A biomaterial disclosed herein can be one or multiple layers. For example, a biomaterial of the disclosure can comprise at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 layer(s); and / or at most 10, at most 9, at most 8, at most 7, at most 6, at most 5, at most 4, at most 3, at most 2, or at most 1 layer(s) shows a head-on view, while FIG. 2B and shows a rotated view of a single layer article. A non-limiting example of a multiple layer biomaterial is shown in FIG. 3. FIG. 3 depicts a layered biomaterial containing three layers of the biomaterial described in FIG. 1, with each layer offset by about 30 degrees.

[0095] FIG. 4A shows a photograph of an approximately 2 x 2 cm 3-D printed, PCL-based surgical mesh of the disclosure. FIG. 4B shows a side view showing the thickness of the 2 x 2 cm 3-D-printed surgical mesh of FIG. 4A. In some embodiments, the biomaterial has a thickness from about 0.4 mm to about 0.8 mm. In some embodiments, the thickness of the biomaterial may be selected depending on the desired drug dose.Intra-material diffusion

[0096] In some embodiments, a biomaterial disclosed herein modulates the diffusion of a therapeutic agent within and from the biomaterial. A non-limiting example of an intramaterial diffusion pattern of a therapeutic agent through a biomaterial disclosed herein (the biomaterial depicted in FIG. 1A) is shown in FIG. IB. In FIG. 1A and FIG. IB, filled hexagonal elements (103) and diamond shaped elements (b) contain the bulk of the therapeutic agent per unit of the biomaterial, although the edges defining the elements also contain therapeutic agent. In some embodiments, the six filled hexagonal elements canWSGR Docket No. 56745-707.601contain a total of 50-500 mg, 100-400 mg, or 150-250 mg of the therapeutic agent. Each element can contain the same or a different amount of the therapeutic agent. In some embodiments, the therapeutic agent diffuses into the region defined by filled diamond-shaped elements (102), which have a degree of porosity that may be conducive to such diffusion. In some embodiments, a biomaterial disclosed herein may further comprise diamond-filled elements infused with a therapeutic agent (106) that serve as additional reservoirs of the therapeutic agent.Polymers

[0097] The drug delivery system involves the incorporation of drug into a polymeric structure, which can be a nanoparticle, microparticles or a scaffold with two dimensional or three dimensional architecture that facilitates a slow, sustained release of drug in low amounts for longer periods. Polymers play a major role in defining the amount and time of the drug released from the polymer. The Food and Drug Administration approved several biodegradable and biocompatible polymers such as polylactide-co-glycolide (PLGA), polycaprolactone (PCL), polyglycolide (PGA), polylactide (PLA), which are widely used in drug delivery applications. PCL blended with PLA was approved by FDA as a safe food contact agent for packaging purposes.

[0098] In some embodiments, a polymer may be a soft and flexible polymer (e.g., PCL with -60 °C glass transition temperature and a melting point of 60 °C). The polymer may be characterized to have a glass transition temperature of less than about 37 degrees, less than about 35 degrees, less than about 30 degrees, less than about 20 degrees, less than about 10 degrees, less than about 5 degrees, less than about 2 degrees, less than about 1 degrees, less than about 0.5 degrees, 0.1 degrees, less than about 0 degrees, less than about - 1 degrees, less than about - 2 degrees, less than about - 5 degrees, less than about - 10 degrees, less than about - 20 degrees, less than about - 30 degrees, less than about - 40 degrees, less than about - 50 degrees, less than about - 60 degrees, less than about - 70 degrees, less than about - 80 degrees, less than about - 90 degrees, or less than about - 100 degrees. In some embodiments, the melting point of this polymer varies with respect to the molecular weight or molecular number. As the molecular weight is higher, the viscosity may be higher. The molecular weight of the polymer (e.g., PCL) plays a crucial role in drug release and degradation rate. The polymer can undergo a two-step degradation: first, hydrolytic cleavage of chemical bond groups (e.g., ester groups) and second, intracellular degradation for the polymer (e.g., PCL) with molecular weights less than 3000. The polymer (e.g., PCL) canWSGR Docket No. 56745-707.601degrade faster outside the human body than inside due to degradation by bacterial enzymes. The other factors include the geometry of the polymer structure and the microenvironment of the implanted site in the human body. For example, for PCL, the hydroxyl radical (OH*) may be a primary component for degradation of PCL in implantable devices. The molecular weight of the polymer (e.g., PCL) can play an important role in defining the release profile of the drug in delivery devices.

[0099] A size of a polymer (e.g., a number average molar mass of the polymer, such as that of PCL) can have an effect on release profile (e.g., release rate) of a drug (e.g., 5-fluorouracil, Gemcitabine, etc.) from the biomaterial comprising the polymer, as disclosed herein. In some embodiments, the PCL molecular weight affects the drug release profile in vitro.

[0100] Biomaterials described herein can be formed from a 3D printed polymer material. In some embodiments, the polymer material can comprise bioresorbable and / or biodegradable polymers, or a mixture of polymers including one or more bioresorbable and / or biodegradable polymers.

[0101] Suitable polymers include, but are not limited to, polycaprolactone (PCL), poly(lactic acid) (PLA), poly(lactic-co-glycolic acid), referred to interchangeably as poly(lactide-co-glycolide) (PLGA), poly(ethylene glycol) diacrylate (PEGDA) and poly(ester amide) copolymers (PEA).

[0102] In some embodiments, the polymer material may comprise or consist of PCL. In some embodiments, the polymer material may be a blend of PCL with one or more additional polymers. In some embodiments, the one or more additional polymers blended with the PCL may be selected from PLA, PLGA, and PEGDA. In some embodiments, the one or more additional polymers blended with the PCL may be selected from polyvinyl chloride and polyethlyene oxide (PEO), or from PEA, polyesters, poly(alpha-hydroxy acids), polylactones, polyorthoesters, polycarbonates, polyanhydrides, polyphosphazenes, or a gelatin based polymer such as polyethylene glycol) (PEG)-gelatin methacrylate.

[0103] In some embodiments, the polymer material may be a blend of a first polymer and a second polymer (e.g., PCL and PLGA), for example a blend of 1 : 1 to 10: 1 first polymer: second polymer (or 1P:2P) (e.g., PCL:PLGA). In some embodiments, the polymer material may comprise a 1 : 1-5 : 1 mixture of 1P:2P or a 1 : 1-2: 1 mixture of 1P:2P. In some embodiments, one of the first and second polymers may be a copolymer (e.g., PLGA), and the ratio of monomers of the copolymer (e.g., lactide and glycolide of the PLGA) may be varied to modulate release of the therapeutic agent and degradation time of the article in situ. The percentage of the copolymer (e.g., PLGA) in the blend can determine the density of theWSGR Docket No. 56745-707.601co-polymer, and the ratio of 1P:2P can indicate the number of elongated (stretched) polymer fibers present in the co-polymer. An increased number of elongated fibers throughout the polymeric article can allow greater drug release from the article. In some embodiments, the copolymer % weight ratio may be from 50:50 to 90:10 monomer l:monomer 2 (e.g., lactide / glycolide for PLGA), from 55:45 to 90: 10 (monomer 1 :monomer 2), from 60:40 to 90:10 (monomer l:monomer 2), from 65:35 to 90:10 (monomer l:monomer 2), from 70:30 to 90:10 (monomer 1 : monomer 2), from 50:50 to 85:15 (monomer 1 : monomer 2), from 50 : 50 to 80:20 (monomer l:monomer 2), from 55:45 to 85:15 (monomer l:monomer 2), from 60:40 to 80:20 (monomer l:monomer 2), or from 65:35 to 75:25 (monomer 1 / monomer 2). In some embodiments, the PLGA % weight ratio may be 85: 15 lactide / glycolide or 60:40 lactide / glycolide.

[0104] Modulation of the density and / or porosity of a polymer material can modulate the release of a therapeutic agent from a biomaterial. For example, release of a therapeutic agent can be increased by increasing the pore size and / or increasing the porosity of the polymer material. In some embodiments, the polymer material (e.g., PCL) can comprise micropores in the range of 50-250 micrometers (pm) in size, with an average size of about 80 microns. The micropores of the polymer material can have a size from 50 to 250 pm, from 50 to 200 pm, from 50 to 150 pm, from 75 to 250 pm, from 75 to 200 pm, from 75 to 150 pm, from 100 to 250 pm, from 100 to 200 pm, from 100 to 150 pm, or from 125 to 225 pm. The micropores of the polymer can have an average (or median) size of at least about 10 pm, at least about 20 pm, at least about 30 pm, at least about 40 pm, at least about 50 pm, at least about 60 pm, at least about 70 pm, at least about 80 pm, or at least about 90 pm; and / or at most about 90 pm, at most about 80 pm, at most about 70 pm, at most about 60 pm, at most about 50 pm, at most about 40 pm, at most about 30 pm, at most about 20 pm, or at most about 10 pm.Blending a polymer with another polymer can yield larger pores. For example, blending the PCL with another polymer, such as PLA, PLGA, PEGDA, or PEO, yields larger pores.Larger pores, for example, can have a size in the range of 200 to 800 microns. The larger pores can have a size from 200 to 800 pm, from 200 to 700 pm, from 200 to 600 pm, from 250 to 800 pm, from 250 to 700 pm, from 250 to 600 pm, from 300 to 800 pm, from 300 to 700 pm, from 300 to 600 pm, or from 350 to 750 pm. In some embodiments, a less porous polymer material can be used to slow release of a therapeutic agent. For example, a polymer material that comprises from about 60% to 100% PCL, or from 60-80% PCL, or from 80-100% PCL can be used.WSGR Docket No. 56745-707.601

[0105] In some embodiments, a biomaterial of the disclosure can comprise geometric elements that each comprise two or more different polymer materials. For example, the polymer material forming the element edges can differ from the polymer material forming the ‘fill’ of a filled element, and different filled elements can be filled with different polymer materials. The polymer materials can differ, for example, in the type of polymer or mixture of polymers making up the polymer material. Additionally, the polymer materials forming the different portions of geometric elements can have different densities and / or porosities and can also differ in the optional additives they contain. For example, a multi-head 3D printer can allow for different substances to be printed simultaneously. For example, each head can contain different components so one head can contain the polymer and therapeutic agent of choice and a second head can contain only polymer. As an STL file is converted into G-code, programmable code for the multi-head printer is created allowing the 3D printer to read which article segments contain PCL and which article segments contain PCL and drug (as programmed). Similarly, more than one drug can be printed at a time. For example, an analgesic (e.g., NSAID) can be printed simultaneously with a chemotherapy drug (e.g. 5-fluorouracil).

[0106] In some embodiments, a biomaterial may comprise a polymer (e.g., a first polymer and / or a second polymer disclosed herein), and the polymer has a number average molar mass of at least 0.5 kilodalton (kDa), at least 1 kDa, at least 2 kDa, at least 5 kDa, at least 7 kDa, at least 10 kDa, at least 20 kDa, at least 30 kDa, at least 40 kDa, at least 50 kDa, at least 70 kDa, at least 100 kDa, at least 200 kDa, at least 500 kDa, at least 700 kDa, or at least 1,000 kDa.

[0107] In some embodiments, a biomaterial may comprise a polymer (e.g., a first polymer and / or a second polymer disclosed herein), and the polymer has a number average molar mass of at most 1 kilodalton (kDa), at most 2 kDa, at most 5 kDa, at most 7 kDa, at most 10 kDa, at most 20 kDa, at most 30 kDa, at most 40 kDa, at most 50 kDa, at most 70 kDa, at most 100 kDa, at most 200 kDa, at most 500 kDa, at most 700 kDa, or at most 1,000 kDa.

[0108] In some embodiments, a biomaterial may comprise a polymer (e.g., a first polymer and / or a second polymer disclosed herein), and the polymer has a number average molar mass of about 1 kilodalton (kDa), about 2 kDa, about 5 kDa, about 7 kDa, about 10 kDa, about 20 kDa, about 30 kDa, about 40 kDa, about 50 kDa, about 70 kDa, about 100 kDa, about 200 kDa, about 500 kDa, about 700 kDa, or about 1,000 kDa.

[0109] In some embodiments, a biomaterial may comprise a first polymer and a second polymer, and the first polymer and the second polymer each have a number average molarWSGR Docket No. 56745-707.601mass of at least 0.5 kilodalton (kDa), at least 1 kDa, at least 2 kDa, at least 5 kDa, at least 7 kDa, at least 10 kDa, at least 20 kDa, at least 30 kDa, at least 40 kDa, at least 50 kDa, at least 70 kDa, at least 100 kDa, at least 200 kDa, at least 500 kDa, at least 700 kDa, or at least 1,000 kDa.

[0110] In some embodiments, a biomaterial may comprise a first polymer and a second polymer, and the first polymer and the second polymer each have a number average molar mass of at most 1 kilodalton (kDa), at most 2 kDa, at most 5 kDa, at most 7 kDa, at most 10 kDa, at most 20 kDa, at most 30 kDa, at most 40 kDa, at most 50 kDa, at most 70 kDa, at most 100 kDa, at most 200 kDa, at most 500 kDa, at most 700 kDa, or at most 1,000 kDa.[OHl] In some embodiments, a biomaterial may comprise a first polymer and a second polymer, and the first polymer and the second polymer each have a number average molar mass of about 1 kilodalton (kDa), about 2 kDa, about 5 kDa, about 7 kDa, about 10 kDa, about 20 kDa, about 30 kDa, about 40 kDa, about 50 kDa, about 70 kDa, about 100 kDa, about 200 kDa, about 500 kDa, about 700 kDa, or about 1,000 kDa.Additives

[0112] In some embodiments a biomaterial of the disclosure, or portions thereof, can comprise one or more additives. A biomaterial can comprise at least 1, at least 2, at least 3, at least 4, or at least 5 additive(s); and / or at most 5, at most 4, at most 3, at most 2, or at most 1 additive(s). The amount of the additive(s) in a biomaterial can be at least 0.1%, at least 0.2%, at least 0.5%, at least 1%, at least 2%, at least 5%, at least 10%, at least 20%, or at least 30% by weight of the biomaterial; and / or at most 30%, at most 20%, at most 10%, at most 5%, at most 2%, at most 1%, at most 0.5%, at most 0.2%, or at most 0.1% by weight of the biomaterial. Non-limiting examples of additives include a radiopaque agent, a colorant, an oil (e.g., silicone) and a porogen.

[0113] The density and / or porosity of the polymer material, and therefore the release of the therapeutic agent from the surgical article, can be modulated by including one or more additives, such as a porogen, in the polymer material. In some embodiments, the polymer material, or at least a portion of the polymer material, may comprise a porogen. The term “porogen” refers to a material that diffuses, dissolves, and / or degrades leaving pores within the polymer material. In some embodiments, a 3D printed surgical article as described herein can be printed with at least a portion of polymer material comprising a porogen. Depending on the porogen used, the porogen can subsequently, either prior to implantation, or after implantation, diffuse, dissolve, and / or degrade, leaving behind pores in the surgical article.WSGR Docket No. 56745-707.601Non-limiting examples of porogens include, water soluble materials such as salts, polysaccharides, water soluble inorganic materials such as bioactive glass, silicate-based nanoparticles, such as lithium sodium magnesium silicate (Laponite™) and water soluble or physiologically labile natural or synthetic polymers, including for example, poly(vinylpyrollidone), pullulan, poly(glycolide), poly(lactide), poly(lactide-co-glycolide), other polyesters, and starches.

[0114] In some embodiments, a porogen of the disclosure may be a bioactive glass such as a ceramic within the Na-Ca-Si-P-0 system. In embodiments, the bioactive glass may comprise SiCh and CaO. In embodiments, the bioactive glass may further comprise Na?O and P2O5. In some embodiments, the bioactive glass may be selected from Bioglass®, bioactive glass 45 S5 (45 wt% SiCh, 24.5 wt% CaO, 24.5 wt% Na?O and 6.0 wt% P2O5), bioactive glass 58S, 60 wt% SiO2, 36 wt% CaO and 4 wt% P2O5, bioactive glass 70S30C,70 wt% SiO2, and 30 wt% CaO, bioactive glass S53P4, 53 wt% SiO2, 23 wt% Na2O, 20 wt% CaO and 4 wt% P2O5 (anti-bacterial), and laponite (Na+o.7(SisMg5.5Lio.3)02o(OH)4] ".

[0115] In some embodiments, a sacrificial or fugitive ink can be used to introduce pores or channels into a polymer material. Non-limiting examples of materials that can serve as fugitive inks include poloxamers, such as Pluronic™ F127, which consists of hydrophobic polypropylene oxide) (PPO) and hydrophilic poly(ethylene oxide) (PEO) segments arranged in a PEO-PPO-PEO configuration.Therapeutic agents

[0116] Biomaterials described here can comprise a therapeutically-effective amount of one or more therapeutic agents. In some embodiments, therapeutic agents are loaded into solid regions of geometric elements of the biomaterial. In some embodiments, the therapeutic agent(s) can be contained within the borders (e.g. a porous border) forming the edges of one or more geometric elements of the article.

[0117] In some embodiments, the one or more therapeutic agents are selected from an anticancer agent, an antimicrobial agent, an antibiotic, a local anesthetic or analgesic, a statin, and an anti-inflammatory agent.

[0118] In some embodiments, the anti-cancer agent may be selected from capecitabine, cisplatin, carboplatin, cyclophosphamide, docetaxel, doxorubicin, etoposide, fluorouracil, floxuridine, gemcitabine, ifosfamide, irinotecan, methotrexate, oxaliplatin, paclitaxel, pemetrexed, raltitrexed, regorafenib, vincristine, vinorelbine, and combinations thereof.WSGR Docket No. 56745-707.601

[0119] In some embodiments, the antimicrobial agent may be an antibiotic. In some embodiments, the antibiotic can be a broad spectrum antibiotic, such as gentamicin, clindamycin, and erythromycin, or a gram positive and gram negative family antibiotic such as an ampicillin and a cephalosporin. Non-limiting examples of antibiotics suitable for the uses herein include penicillin V potassium, cioxacillin sodium, dicloxacillin sodium, oxacillin sodium, carbenicillin indanyl sodium, oxytetracycline, hydrochloride, tetracycline hydrochloride, clindamycin phosphate, clindamycin, hydrochloride, clindamycin palmitate HCL, lincomycin HCL, novobiocin sodium, nitrofurantoin sodium, and metronidazole hydrochloride.

[0120] In some embodiments, a therapeutic agent may be a local anesthetic or analgesic. Non-limiting examples of local anesthetics or analgesics include lidocaine, bupivacaine, tetracaine, ropivacaine, benzocaine, and fentanyl, codeine hydrochloride, codeine phosphate, codeine sulphate, dextromoramide tartrate, hydrocodone bitartrate, hydromorphone hydrochloride, pethidine hydrochloride, methadone hydrochloride, morphine sulphate, morphine acetate, morphine lactate, morphine meconate, morphine nitrate, morphine monobasic phosphate, morphine tartrate, morphine valerate, morphine hydrobromide, morphine hydrochloride, and propoxyphene hydrochloride.

[0121] In some embodiments, a therapeutic agent may be an anti-inflammatory agent. An anti-inflammatory agent can be selected from a non-steroidal anti-inflammatory agent. Nonlimiting examples of non-steroidal anti-inflammatory agents include choline salicylate, ibuprofen, ketoprofen, magnesium salicylate, meclofenamate sodium, naproxen sodium, and tolmetin sodium. In some embodiments, the one or more anti-inflammatory substances may be selected from a non-specific anti-inflammatory such as ibuprofen and aspirin, or a COX-2 specific inhibitor such as rofecoxib and celecoxib.

[0122] In some embodiments, a therapeutic agent may be an anti-cancer agent. In some embodiments, an anti-cancer agent may be selected from an agent used in treating colorectal cancer. In some embodiments, the anti-cancer agent may be selected from gemcitabine (Gemzar™), raltitrexed (Tomudex™) oxaliplatin (Eloxatin™), regorafenib, irinotecan (Camptostar™), and 5 -fluorouracil (Adrucil™), and combinations thereof. In some embodiments, the anti-cancer agent may be selected from capecitabine, fluorouracil, irinotecan and oxaliplatin, and combinations thereof.

[0123] In some embodiments, the anti-cancer agent may be selected from an agent used in treating pancreatic cancer. In some embodiments, the anti-cancer agent may be selected from gemcitabine (Gemzar™), fluorouracil (5-FU), irinotecan (Camptosar™), oxaliplatinWSGR Docket No. 56745-707.601(El oxatin™), paclitaxel (Taxol™ or Abraxane™), capecitabine (Xeloda™) cisplatin, docetaxel (Taxotere™), and irinotecan (Onivyde™), and combinations thereof.

[0124] In some embodiments, the anti-cancer agent may be selected from an agent used in treating lung cancer. In some embodiments, the anti-cancer agent may be selected from cisplatin (Platinol™), carboplatin (Paraplatin™), docetaxel (Taxotere™), gemcitabine (Gemzar™), paclitaxel (Taxol™ and others), vinorelbine (Navelbine™ and others), pemetrexed (Alimta™), and combinations thereof.

[0125] In some embodiments, the anti-cancer agent may be selected from an agent used in treating bone cancer. In some embodiments, the anti-cancer agent may be selected from doxorubicin (Adriamycin®), cisplatin, etoposide (VP-16), ifosfamide (Ifex®), cyclophosphamide (Cytoxan®), methotrexate, and vincristine (Oncovin®), and combinations thereof.

[0126] In some embodiments, a therapeutic agent may comprise a cell (e.g. a human cell). For example, the one or more therapeutic agents of a biomaterial can be selected from, pluripotent stem cells, multipotent stem cells, and induced pluripotent stem cells (iPSCs).

[0127] In some embodiments, a biomaterial may comprise a geometric element (e.g., a first or second geometric element disclosed herein), a polymer (e.g., a first or second polymer disclosed herein), and a therapeutic agent, and an amount of the therapeutic agent in the biomaterial, geometric element, or polymer is at least 1%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% by weight of the biomaterial, geometric element, or polymer.

[0128] In some embodiments, a biomaterial may comprise a geometric element (e.g., a first or second geometric element disclosed herein), a polymer (e.g., a first or second polymer disclosed herein), and a therapeutic agent, and an amount of the therapeutic agent in the biomaterial, geometric element, or polymer is at most 1%, at most 5%, at most 10%, at most 15%, at most 20%, at most 25%, at most 30%, at most 35%, at most 40%, at most 45%, at most 50%, at most 55%, at most 60%, at most 65%, at most 70%, at most 75%, at most 80%, at most 85%, at most 90%, or at most 95% by weight of the biomaterial, geometric element, or polymer.

[0129] In some embodiments, a biomaterial may comprise a geometric element (e.g., a first or second geometric element disclosed herein), a polymer (e.g., a first or second polymer disclosed herein), and a therapeutic agent, and an amount of the therapeutic agent in theWSGR Docket No. 56745-707.601biomaterial, geometric element, or polymer is about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% by weight of the biomaterial, geometric element, or polymer.

[0130] In some embodiments, a biomaterial may comprise a geometric element (e.g., a first or second geometric element disclosed herein), a first polymer, a second polymer, and a therapeutic agent, and an amount of the therapeutic agent in the biomaterial, geometric element, or polymer is at least 1%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% by weight of a combination of the first polymer and the second polymer.

[0131] In some embodiments, a biomaterial may comprise a geometric element (e.g., a first or second geometric element disclosed herein), a first polymer, a second polymer, and a therapeutic agent, and an amount of the therapeutic agent in the biomaterial, geometric element, or polymer is at most 1%, at most 5%, at most 10%, at most 15%, at most 20%, at most 25%, at most 30%, at most 35%, at most 40%, at most 45%, at most 50%, at most 55%, at most 60%, at most 65%, at most 70%, at most 75%, at most 80%, at most 85%, at most 90%, or at most 95% by weight of a combination of the first polymer and the second polymer.

[0132] In some embodiments, a biomaterial may comprise a geometric element (e.g., a first or second geometric element disclosed herein), a first polymer, a second polymer, and a therapeutic agent, and an amount of the therapeutic agent in the biomaterial, geometric element, or polymer is about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% by weight of a combination of the first polymer and the second polymer.Formulation

[0133] A formulation of the biomaterial (e.g., drug delivery article or chip) as disclosed herein can comprise one or more polymers (e.g., PCL) and a drug substance (e.g., 5-fluorouracil, gemcitabine). The formulation can comprise polymer molecular weights (e.g., number average molar mass) and / or the active pharmaceutical ingredient (API) ratio selected to allow controlled release of the drug substance post placement (e.g., over 4 weeks). The components can be homogeneously combined and aseptically manufactured, e.g., 3D printed.WSGR Docket No. 56745-707.601

[0134] In some embodiments, the biomaterial can comprise the impermeable layer that exists within the biomaterial constructed from higher molecular weight polymer (e.g., PCL 50,000) with no drug. In some embodiments, the biomaterial can comprise one or more permeable layers constructed from one or more higher molecule weight polymers (e.g., PCL 50,000) with one or more drugs. In some embodiments, the biomaterial can comprise one or more additional permeable layers constructed from one or more lower molecule weight polymers (e.g., PCL 37,000) with one or more drugs. Various suitable compounds can be included within this formulation.

[0135] Additional (or alternative) embodiments of the biomaterial as disclosed herein are in FIG. 6, wherein the darker shading can refer to loading of one or more therapeutic agents (e.g., 5-fluorouracil, gemcitabine).

[0136] In some embodiments, as shown in FIG. 7, the biomaterial as disclosed herein can comprise a plurality of portions (e.g., north or N, south or S, west or W, east or E, etc.) capable of comprising drugs (e.g., 5-fluorouracil, gemcitabine). In some embodiments, the drugs can be loaded to one or more portions of the plurality of portions of the biomaterial. In some embodiments, the drugs can be loaded to two or more portions of the plurality of portions of the biomaterial. The two or more portions can comprise a first portion and a second portion, and the first portion and the second portion can be characterized by having (1) different polymers, (2) same polymers but having different number average molecular weight, (3) different drugs, (4) same drug but having different loading amount, and / or (5) different weight ratios between the polymer and the drug within each portion.In some examples, a biomaterial can be loaded with a drug (e.g., 5-fluorouracil) in four different portions: N, S, E, and W. The portions N and S can have substantially the same parameters: (i) comprising a high molecular weight polymer (e.g., PCL having a number average molecular weight of about 50,000 Dalton), and (ii) comprising substantially the same ratio between such polymer and the loaded drug (e.g., a weight ratio of about 1:0.73 (polymer: drug), such as about 19 milligrams PCL and about 14 milligrams drug). In addition, the portions E and W can have substantially the same parameters: (i) comprising a low molecular weight polymer (e.g., PCL having a number average molecular weight of about 37,000 Dalton), and (ii) comprising substantially the same ratio between such polymer and the loaded drug (e.g., a weight ratio of about 1:0.50 (polymer: drug), such as about 12 milligrams PCL and about 6 milligrams drug). The biomaterial can comprise an additional region (e.g., frame) that surrounds at least a portion of one or more of the four different portions, and the additional region can be loaded with a drug. Alternatively, the additional region can beWSGR Docket No. 56745-707.601substantially free of any active agents. The additional region can be characterized by (i) comprising a high molecular weight polymer (e.g., PCL having a number average molecular weight of about 50,000 Dalton, and 45 milligrams of such polymer), and (ii) substantially free of the drug.

[0137] In some embodiments, a biomaterial can be loaded with a drug (e.g., 5 -fluorouracil) in one or more of four different portions: N, S, E, and W. The portions N and S can have substantially the same parameters: (i) comprising a high molecular weight polymer (e.g., PCL having a number average molecular weight of about 50,000 Dalton), and (ii) comprising substantially the same ratio between such polymer and the loaded drug (e.g., a weight ratio of about 2:0.73 (polymer: drug), such as about 40 milligrams PCL and about 14 milligrams drug). In addition, the portions E and W can have substantially the same parameters: (i) comprising a low molecular weight polymer (e.g., PCL having a number average molecular weight of about 37,000 Dalton), and (ii) comprising substantially the same ratio between such polymer and the loaded drug (e.g., a weight ratio of about 2:0.50 (polymer: drug), such as about 24 milligrams PCL and about 6 milligrams drug). The biomaterial can comprise an additional region (e.g., frame) that surrounds at least a portion of one or more of the four different portions, and the additional region can be loaded with a drug. Alternatively, the additional region can be substantially free of any active agents. The additional region can be characterized by (i) comprising a high molecular weight polymer (e.g., PCL having a number average molecular weight of about 50,000 Dalton, and 90 milligrams of such polymer), and (ii) substantially free of the drug. Table 1 shows example polymers in different regions of the drug delivery article.Table 1. Example polymer in different regions of the drug delivery articleImpermeable layer (lighter Permeable section (darker Permeable section 2 (darker section) section on the top) section on the bottom) 50,000 37,000 50,00050,000 50,000 50,00050,000 25,000 37,00050,000 37,000 25,00037,000 50,000 37,000WSGR Docket No. 56745-707.60137,000 37,000 50,00050,000 50,000 50,00050,000 50,000 37,000

[0138] If the drug molecule is above (») dKA weight, a lower molecular weight polymer can be utilized for the permeable layer (ability to have more pores). If the drug molecule is too small (« dKA weight), a higher molecular weight polymer can be utilized for the permeable layer.

[0139] In some embodiments, additional aspects of the biomaterial as disclosed herein can be changed for drug loadability, including, but not limited to, size of a polymer of the biomaterial, size of the therapeutic agent, polarity (or charge) of the biomaterial, polarity (or charge) of the therapeutic agent, and / or printability (e.g., ability to withstand manufacturing process and temperature) of the polymer of the biomaterial and / or of the therapeutic agent.

[0140] In some embodiments, the lower molecular weight polymers (e.g., PCL of 25,000 and 37,000) are easy to mix with all different weights of polymers and are easier to print compared to higher molecular weight polymers (e.g., 80,000 molecular weight PCL). For example, 50,000 molecular weight PCL is marginally easier to mix compared to 80,000 molecular weight PCL and tougher compared to 25,000 and 37,000 PCL formulations. Upon drug encapsulation and release, the two provide similar release profiles. The PCL lesser than 37,000 and greater than or equal to 50,000 molecular weight may be used to tailor the release profile as 80,000 molecular weight can be difficult to formulate.

[0141] In some embodiments, the biomaterial locally administers one or more drugs to a site of interest without significant release into systemic circulation. In some embodiments, the site of interest may comprise a tumor or other cancerous site. In some embodiments, the biomaterial releases the one or more drugs for a period up to 7 days, up to 14 days, up to 21 days, up to 30 days, up to 40 days, up to 50 days, up to 60 days, up to 60 days, up to 3 months, up to 4 months, up to 6 months, up to 8 months, up to 10 months, up to 1 year, up to 2 years, or up to 3 years.

[0142] In some embodiments, the biomaterial formulated with PCL and 5-FU delivers the chemotherapy agent 5-FU to a tumor or other cancerous site for a period of 30 days. 5-FU functions by disrupting the recycling of uracil, preventing DNA replication and ultimately leading to cell death. In some embodiments, the biomaterial may comprise five sections: a center section referred to as the “skeleton” and 4 drug compartments, which are referred to asWSGR Docket No. 56745-707.601“North,” “South,” “East,” “West” (e.g., top left of FIG. 7). The skeleton may be fabricated from a high molecular weight biocompatible polymer and is suitable to be surgically anchored to the site of interest. There are four suture points located at the comers of this center section that are used to secure the biomaterial (or chip) to the tumor. The North and South compartments are 3D-printed from a combination of 5-FU and the same high molecular weight polymer utilized in the center section. The addition of the drug can cause these two sections to degrade at an accelerated rate relative to the skeleton itself, thereby allowing fast delivery of 5-FU into the tumor. The East and West compartments are printed from a combination of 5-FU and a lower molecular weight polymer. The difference in molecular weight of the two polymers allows for biphasic release, which can be exploited for the administration of multiple drugs in the field of cancer treatment.Methods of fabricating biomaterials

[0143] Also disclosed herein are methods for printing biomaterials of the disclosure. In some embodiments, the biomaterials are printed using an extrusion-based process. Extrusion-based 3D printing can include any of: fused filament fabrication (FFF), fused deposition modeling (FDM), and gel mediums (with or without granules). In some embodiments, the biomaterials are printed using stereolithography or other photopolymerization-based methods. In some embodiments, the biomaterials are printed with free radical-based polymerization methods. In some embodiments, the biomaterials are printed with cationic based polymerization methods. In some embodiments, the biomaterials are printed with anionic based polymerization methods. In some embodiments, the biomaterials are printed with powder-fusion methods. In some embodiments, the biomaterials are printed with powder bed fusion, binder jetting, or selective sintering.

[0144] Printing of a biomaterial can comprise heating a polymer material the polymer’s melting point and combining the polymer with a therapeutic agent, with or without additional ingredients, such as a porogen, to create a suspension of the therapeutic agent in the polymer material. The resulting combination, which is referred to here as a “slurry” can then loaded into a printing head of an extrusion-based 3D printer. The printing head can be, for example, a syringe. Variations of this process include, but are not limited to, combining the polymer material with the therapeutic agent and then heating the combination to the melting point of the polymer material to form the slurry. Additional ingredients, such as a porogen, can be added at any time during the process. The slurry may be extruded onto a substrate along the pre-designed path to form a biomaterial as described herein using a layer by layer process. InWSGR Docket No. 56745-707.601some embodiments, the model for the biomaterial may be obtained by computer aided design (CAD).

[0145] In some embodiments, biomaterials of the disclosure comprise multiple layers. Each layer can have a different geometry (e.g., staggered, slanted). Layered biomaterials can be constructed using a layer-by-layer process to achieve an overall mesh size of, for example, about 4 x about 6 cm x about 0.5 cm (h x w x d).

[0146] In some embodiments, a biomaterial article as described herein may be printed in layers using alternating layers of polymer material with and without the one or more therapeutic agents dispersed in the polymer. For example, (i) a first layer of polymer material containing a therapeutic agent dispersed in the polymer, (ii) a second layer of polymer material without the therapeutic agent, the second layer disposed on the first layer, and (iii) a third layer of polymer material containing the therapeutic agent dispersed in the polymer, the third layer disposed on the second layer. The layers are printed in this sequence, repeating until the article has attained a desired thickness. In some embodiments, the article can have a thickness in the range of from 0.5 to 3.0 cm or from 0.5 to 2.0 cm, or from 0.5 to 1.0 cm.

[0147] In some cases, the biomaterial may be 3D printed using a filament (e.g., a pool of filament) comprising a polymer (or one or more polymers) and a therapeutic agent (or one or more therapeutic agents). In some embodiments, the filament may be generated by directing the polymer and the therapeutic agent into an extruder (e.g., a single-screw extruder) to generate a filament (e.g., a monofilament). Such filament may be fed into a nozzle of a 3D printer to print at least a portion of a biomaterial. In some embodiments, such filament may exhibit greater homogeneous mixing of the therapeutic agent within a matrix of the polymer as compared to a manual or hand-mixed slurry (e.g., not directed through the extruder) of the therapeutic agent with the polymer, e.g., as characterized by (i) having a reduced number (e.g., a single) glass transition (Tg) peak in a differential scanning calorimetry (DSC) assay, (ii) having a homogeneous mixture of a dye in an optical assay, (iii) having a smaller domain size as measured by an imaging assay such as transmission electron microscope (TEM), etc.

[0148] In some cases, the present disclosure provides a method for manufacturing a delivery article as disclosed herein. In some cases, the method may comprise directing a polymer and an active agent into an extruder (e.g., a single screw extruder) to generate a monofilament. In some cases, the method may further comprise directing the first monofilament to a nozzle of a 3D printer to print at least a portion of the delivery article.

[0149] In some cases, the extruder may comprise a hot melt extruder. In some cases, the method of generating the filament may comprise heating and mixing the polymer and theWSGR Docket No. 56745-707.601therapeutic agent (or active agent) in the extruder. In some cases, the method may comprise passing the mixed polymer and active agent through a die to generate the monofilament. In some cases, the method may comprise cooling the monofilament to provide a cooled monofilament. In some cases, the method may comprise collecting the cooled monofilament on a spooler.

[0150] In some cases, the method may comprise generating different monofilaments for printing different portions of the delivery article.

[0151] In some cases, the method may comprise directing a first polymer and a first active agent into an extruder to generate a first monofilament. The first monofilament may be usable for printing a first portion of the delivery article. In some cases, the method may comprise directing a second polymer and a second active agent into the extruder to generate a second monofilament. The second monofilament may be usable for printing a second portion of the delivery article. The second portion may be an active agent containing portion. In some cases, the method may comprise directing a third polymer into the extruder to generate a third monofilament. The third monofilament may be usable for printing a third portion of the delivery article. In some cases, the third portion may be a polymer only portion (e.g., no active agent). In some cases, at least a portion of the third portion may be in contact with at least a portion of the first portion and / or at least a portion of the second portion. In some cases, the third filament may be usable for printing a border of the first portion and / or the second portion. In some cases, the method may comprise directing an additional polymer and an additional active agent into the extruder to generate an additional monofilament. The additional monofilament may be usable for printing an additional portion of the delivery article.

[0152] In some cases, the hot melt extruder may comprise an extruder screw. In some cases, the hot melt extruder may comprise a single-screw hot melt extruder. In some cases, the extruder may comprise a material entry point, a material exit point, and at least one thermal zone disposed between the material entry point and the material exit point. In some cases, the extruder may comprise one or more thermal zones. In some cases, the one or more thermal zones may comprise different heating temperatures. In some cases, the one or more thermal zones may be set at temperatures about or above the glass transition temperature of the polymer. In some cases, the one or more thermal zones may comprise temperatures that are at least about 1 °C, at least about 2 °C, at least about 5 °C, at least about 10 °C, at least about 20 °C, at least about 30 °C, at least about 40 °C, at least about 50 °C, or at least about 100 °C above the glass transition temperature of the polymer fed into the extruder (e.g., the firstWSGR Docket No. 56745-707.601polymer, the second polymer, the third polymer, or the additional polymer). In some cases, the one or more thermal zones may comprise temperatures that are at most about 100 °C, at most about 50 °C, at most about 40 °C, at most about 30 °C, at most about 20 °C, at most about 10 °C, at most about 5 °C, at most about 2 °C, or at most about 1 °C above the glass transition temperature of the polymer fed into the extruder (e.g., the first polymer, the second polymer, the third polymer, or the additional polymer). In some cases, at least two of the thermal zones may be set at same temperature. In some cases, a thermal zone may comprise a temperature lower than the glass transition temperature of the polymer.

[0153] In some cases, the hot melt extruder may comprise a material hopper disposed above the extruder screw. In some cases, the material hopper may comprise a base. In some cases, the hot melt extruder may comprise a motor disposed at the base of the material hopper. In some cases, the motor may mechanically regulate flow from the material hopper to the material entry point of the extruder screw. In some cases, the hot melt extruder may comprise a die operably connected to the material exit point of the extruder screw. In some cases, the hot melt extruder may comprise an air blower positioned to blow air on material that passes through the die. In some cases, the hot melt extruder may comprise a conveyor belt positioned to receive material that passes through the die. In some cases, the conveyor belt may convey material from the die to a spooler. In some cases, the hot melt extruder may comprise a spooler, positioned to receive material from the conveyor belt and spool the material on the spooler.

[0154] In some cases, the first monofilament may comprise a cross-sectional diameter from about 1 mm to about 1 cm. In some cases, the first monofilament may comprise a cross-sectional diameter of at least about 0.1 mm, at least about 0.2 mm, at least about 0.5 mm, at least about 1 mm, at least about 2 mm, at least about 3 mm, at least about 4 mm, at least about 5 mm, or at least about 1 cm. In some cases, the first monofilament may comprise a cross-sectional diameter of at most about 1 cm, at most about 5 mm, at most about 2 mm, at most about 1 mm, at most about 0.5 mm, at most about 0.2 mm, or at most about 0.1 mm. In some cases, the second monofilament may comprise a cross-sectional diameter from about 1 mm to about 1 cm. In some cases, the second monofilament may comprise a cross-sectional diameter of at least about 0.1 mm, at least about 0.2 mm, at least about 0.5 mm, at least about 1 mm, at least about 2 mm, at least about 3 mm, at least about 4 mm, at least about 5 mm, or at least about 1 cm. In some cases, the second monofilament may comprise a cross-sectional diameter of at most about 1 cm, at most about 5 mm, at most about 2 mm, at most about 1 mm, at most about 0.5 mm, at most about 0.2 mm, or at most about 0.1 mm. In some cases,WSGR Docket No. 56745-707.601the third monofilament may comprise a cross-sectional diameter from about 1 mm to about 1 cm. In some cases, the third monofilament may comprise a cross-sectional diameter of at least about 0.1 mm, at least about 0.2 mm, at least about 0.5 mm, at least about 1 mm, at least about 2 mm, at least about 3 mm, at least about 4 mm, at least about 5 mm, or at least about 1 cm. In some cases, the third monofilament may comprise a cross-sectional diameter of at most about 1 cm, at most about 5 mm, at most about 2 mm, at most about 1 mm, at most about 0.5 mm, at most about 0.2 mm, or at most about 0.1 mm. In some cases, the additional monofilament may comprise a cross-sectional diameter from about 1 mm to about 1 cm. In some cases, the additional monofilament may comprise a cross-sectional diameter of at least about 0.1 mm, at least about 0.2 mm, at least about 0.5 mm, at least about 1 mm, at least about 2 mm, at least about 3 mm, at least about 4 mm, at least about 5 mm, or at least about 1 cm. In some cases, the additional monofilament may comprise a cross-sectional diameter of at most about 1 cm, at most about 5 mm, at most about 2 mm, at most about 1 mm, at most about 0.5 mm, at most about 0.2 mm, or at most about 0.1 mm.

[0155] In some cases, the method may comprise directing the first monofilament to a nozzle of the 3D printer to print at least a portion of the first portion (or the entire first portion). In some cases, the method may comprise directing the second monofilament to a nozzle of the 3D printer to print at least a portion of the second portion (or the entire second portion). In some cases, the method may comprise directing the third monofilament to a nozzle of the 3D printer to print at least a portion of the third portion (or the entire third portion) or a border of the first portion and / or the second portion. In some cases, the border of the first portion and the second portion may be printed with different monofilament. In some cases, the method may comprise directing the additional monofilament to a nozzle of the 3D printer to print at least a portion of the additional portion.

[0156] In some cases, a 3D printing method may comprise receiving in computer memory a computational representation of the 3D object (e.g., delivery article of a layer thereof). In some cases, the method may comprise directing a monofilament (e.g., the first, second, third, or additional monofilament) through a feeder (or nozzle) of a print head and in contact with a print bed (or support). In some cases, the method may comprise heating the monofilament to melt at least a portion of the monofilament. In some cases, the method may comprise using a power supply to flow electrical current through the monofilament and the print bed while the monofilament is in contact with the print bed. In some cases, the method may comprise subjecting the monofilament to a heating (e.g., Joule heating, conductive heating) upon flow of electrical current through the monofilament and the print bed. The heating may beWSGR Docket No. 56745-707.601sufficient to melt at least a portion of the monofilament. In some cases, the method may comprise depositing the at least the portion of the monofilament adjacent to the print bed to print at least a portion of the 3D object (e.g., the delivery article or a layer thereof) in accordance with the computational representation of the 3D object. In some cases, a size of the at least the portion of the monofilament may be controllable relative to the monofilament during deposition. In some cases, the 3D printer may comprise a single print head and the portions of the delivery article may be printed sequentially. In some cases, the 3D printer may comprise multiple print heads such that more than one portions of the delivery article may be printed simultaneously.

[0157] In some embodiments, at least a portion of a biomaterial may be 3D printed based on a slurry, while at least an additional portion of the same biomaterial may be 3D printed based on a filament generated via the screw extrusion process. In some embodiments, at least a portion of a biomaterial may be 3D printed based on a filament made form the slurry, while at least an additional portion of the same biomaterial may be 3D printed based on a filament generated via the screw extrusion process. In some embodiments, at least a portion of a biomaterial may be 3D printed based on a mixture of a slurry and a filament generated via the screw extrusion process, e.g., a 3D print head configured to receive both the slurry and the filament and output a mixture melt of the two through the nozzle and onto or towards a printing substrate.Bioprinting Parameters

[0158] Alternatively or in addition to the filament-based 3D printing method as provided herein, the method disclosed herein can utilize a needle in a bioprinting process. In some embodiments, one or more polymeric materials, fugitive inks, ECM materials, cell suspensions, or a combination thereof may be deposited through a needle onto a substrate. A method of the disclosure can print from more than one needle, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more needles. In some embodiments, a needle used in a method disclosed herein has a diameter that is expressed using the Birmingham gauge system. In some embodiments, a needle has a diameter of 7 gauge, 8 gauge, 9 gauge, 10 gauge, 11 gauge, 12 gauge, 13 gauge, 14 gauge, 15 gauge, 16 gauge, 17 gauge, 18 gauge, 19 gauge, 20 gauge, 21 gauge, 22 gauge, 22s gauge, 23 gauge, 24 gauge, 25 gauge, 26 gauge, 26s gauge, 27 gauge, 28 gauge, 29 gauge, 30 gauge, 31 gauge, 32 gauge, 33 gauge, or 34 gauge.

[0159] In some embodiments, a needle of the disclosure has a diameter of between 0.1 mm to 400 mm. In some embodiments, a needle of the disclosure has a diameter of between 0.1 mmWSGR Docket No. 56745-707.601to 0.5 mm, between 0.1 mm to 1 mm, between 0.1 mm to 10 mm, between 0.1 mm to 20 mm, between 0.1 mm to 30 mm, between 0.1 mm to 40 mm, between 0.1 mm to 50 mm, between 0.1 mm to 100 mm, between 0.1 mm to 200 mm, between 0.1 mm to 300 mm, between 0.1 mm to 400 mm, between 0.5 mm to 1 mm, between 0.5 mm to 10 mm, between 0.5 mm to 20 mm, between 0.5 mm to 30 mm, between 0.5 mm to 40 mm, between 0.5 mm to 50 mm, between 0.5 mm to 100 mm, between 0.5 mm to 200 mm, between 0.5 mm to 300 mm, between 0.5 mm to 400 mm, between 1 mm to 10 mm, between 1 mm to 20 mm, between 1 mm to 30 mm, between 1 mm to 40 mm, between 1 mm to 50 mm, between 1 mm to 100 mm, between 1 mm to 200 mm, between 1 mm to 300 mm, between 1 mm to 400 mm, between 10 mm to 20 mm, between 10 mm to 30 mm, between 10 mm to 40 mm, between 10 mm to 50 mm, between 10 mm to 100 mm, between 10 mm to 200 mm, between 10 mm to 300 mm, between 10 mm to 400 mm, between 20 mm to 30 mm, between 20 mm to 40 mm, between 20 mm to 50 mm, between 20 mm to 100 mm, between 20 mm to 200 mm, between 20 mm to 300 mm, between 20 mm to 400 mm, between 30 mm to 40 mm, between 30 mm to 50 mm, between 30 mm to 100 mm, between 30 mm to 200 mm, between 30 mm to 300 mm, between 30 mm to 400 mm, between 40 mm to 50 mm, between 40 mm to 100 mm, between 40 mm to 200 mm, between 40 mm to 300 mm, between 40 mm to 400 mm, between 50 mm to 100 mm, between 50 mm to 200 mm, between 50 mm to 300 mm, between 50 mm to 400 mm, between 100 mm to 200 mm, between 100 mm to 300 mm, between 100 mm to 400 mm, between 200 mm to 300 mm, between 200 mm to 400 mm, or between 300 mm to 400 mm. In some embodiments, a needle of the disclosure has a diameter of 0.1 mm, 0.2 mm, 0.5 mm, 1 mm, 10 mm, 20 mm, 30 mm, 40 mm, 50 mm, 100 mm, 200 mm, 300 mm, or 400 mm. In some embodiments, a needle of the disclosure has a diameter of at least 0.1 mm, at least 0.5 mm, at least 1 mm, at least 10 mm, at least 20 mm, at least 30 mm, at least 40 mm, at least 50 mm, at least 100 mm, at least 200 mm, or at least 300 mm. In some embodiments, a needle of the disclosure has a diameter of at most 0.5 mm, at most 1 mm, at most 10 mm, at most 20 mm, at most 30 mm, at most 40 mm, at most 50 mm, at most 100 mm, at most 200 mm, at most 300 mm, or at most 400 mm.

[0160] A method disclosed herein can comprise using an extruder to pass a material through a needle and onto a substrate. In some embodiments, multiple extruders pass one or more materials through one or more needles and deposit one or more materials onto a substrate. For example, the multiple extruders can deposit material simultaneously, sequentially, or via a predefined sequence. In some embodiments, deposition from one or more extruders may beWSGR Docket No. 56745-707.601controlled in real time. In some embodiments, printing may be performed with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more extruders for passing a material through a needle.

[0161] The temperature at which an extruder operates can be controlled. In some embodiments, an extruder operates at a temperature of about 25 °C to about 200 °C. In some embodiments, an extruder operates at a temperature of about 25 °C to about 37 °C, about 25 °C to about 50 °C, about 25 °C to about 75 °C, about 25 °C to about 100 °C, about 25 °C to about 150 °C, about 25 °C to about 200 °C, about 27 °C to about 37 °C, about 27 °C to about 50 °C, about 27 °C to about 75 °C, about 27 °C to about 100 °C, about 27 °C to about 150 °C, about 27 °C to about 200 °C, about 37 °C to about 50 °C, about 37 °C to about 75 °C, about 37 °C to about 100 °C, about 37 °C to about 150 °C, about 37 °C to about 200 °C, about 50 °C to about 75 °C, about 50 °C to about 100 °C, about 50 °C to about 150 °C, about 50 °C to about 200 °C, about 75 °C to about 100 °C, about 75 °C to about 150 °C, about 75 °C to about 200 °C, about 100 °C to about 150 °C, about 100 °C to about 200 °C, or about 150 °C to about 200 °C. In some embodiments, an extruder operates at a temperature of about 25 °C about 27 °C, about 37 °C, about 50 °C, about 65 °C, about 75 °C, about 100 °C, about 150 °C, or about 200 °C. In some embodiments, an extruder operates at a temperature of at least about 25 °C, at least about 27 °C, at least about 37 °C, at least about 50 °C, at least about 75 °C, at least about 100 °C, or at least about 150 °C. In some embodiments, an extruder operates at a temperature of at most about 25 °C, at most about 37 °C, at most about 50 °C, at most about 75 °C, at most about 100 °C, at most about 150 °C, or at most about 200 °C.

[0162] In some embodiments, pressurized air may be used to move a material through an extruder. The air pressure of an extruder can be controlled. In some embodiments, an extruder operates at an air pressure of about 600 kPa to about 800 kPa. In some embodiments, an extruder operates at an air pressure of about 600 kPa to about 625 kPa, about 600 kPa to about 650 kPa, about 600 kPa to about 675 kPa, about 600 kPa to about 700 kPa, about 600 kPa to about 725 kPa, about 600 kPa to about 750 kPa, about 600 kPa to about 775 kPa, about 600 kPa to about 800 kPa, about 625 kPa to about 650 kPa, about 625 kPa to about 675 kPa, about 625 kPa to about 700 kPa, about 625 kPa to about 725 kPa, about 625 kPa to about 750 kPa, about 625 kPa to about 775 kPa, about 625 kPa to about 800 kPa, about 650 kPa to about 675 kPa, about 650 kPa to about 700 kPa, about 650 kPa to about 725 kPa, about 650 kPa to about 750 kPa, about 650 kPa to about 775 kPa, about 650 kPa to about 800 kPa, about 675 kPa to about 700 kPa, about 675 kPa to about 725 kPa, about 675 kPa to about 750 kPa, about 675 kPa to about 775 kPa, about 675 kPa to about 800 kPa, about 700WSGR Docket No. 56745-707.601kPa to about 725 kPa, about 700 kPa to about 750 kPa, about 700 kPa to about 775 kPa, about 700 kPa to about 800 kPa, about 725 kPa to about 750 kPa, about 725 kPa to about 775 kPa, about 725 kPa to about 800 kPa, about 750 kPa to about 775 kPa, about 750 kPa to about 800 kPa, or about 775 kPa to about 800 kPa. In some embodiments, an extruder operates at an air pressure of about 600 kPa, about 625 kPa, about 650 kPa, about 675 kPa, about 689.5 kPa, about 700 kPa, about 717.1 kPa, about 725 kPa, about 750 kPa, about 775 kPa, or about 800 kPa. In some embodiments, an extruder operates at an air pressure of at least about 600 kPa, at least about 625 kPa, at least about 650 kPa, at least about 675 kPa, at least about 700 kPa, at least about 725 kPa, at least about 750 kPa, or at least about 775 kPa. In some embodiments, an extruder operates at an air pressure of at most about 625 kPa, at most about 650 kPa, at most about 675 kPa, at most about 700 kPa, at most about 725 kPa, at most about 750 kPa, at most about 775 kPa, or at most about 800 kPa.

[0163] In some embodiments, an extruder operates at an air pressure of about 60 pounds per square inch (psi) to about 120 psi. In some embodiments, an extruder operates at an air pressure of about 87 psi to about 90.6 psi, about 87 psi to about 94.3 psi, about 87 psi to about 97.9 psi, about 87 psi to about 101.5 psi, about 87 psi to about 105.2 psi, about 87 psi to about 108.8 psi, about 87 psi to about 112.4 psi, about 87 psi to about 116 psi, about 90.6 psi to about 94.3 psi, about 90.6 psi to about 97.9 psi, about 90.6 psi to about 101.5 psi, about 90.6 psi to about 105.2 psi, about 90.6 psi to about 108.8 psi, about 90.6 psi to about 112.4 psi, about 90.6 psi to about 116 psi, about 94.3 psi to about 97.9 psi, about 94.3 psi to about 101.5 psi, about 94.3 psi to about 105.2 psi, about 94.3 psi to about 108.8 psi, about 94.3 psi to about 112.4 psi, about 94.3 psi to about 116 psi, about 97.9 psi to about 101.5 psi, about 97.9 psi to about 105.2 psi, about 97.9 psi to about 108.8 psi, about 97.9 psi to about 112.4 psi, about 97.9 psi to about 116 psi, about 101.5 psi to about 105.2 psi, about 101.5 psi to about 108.8 psi, about 101.5 psi to about 112.4 psi, about 101.5 psi to about 116 psi, about 105.2 psi to about 108.8 psi, about 105.2 psi to about 112.4 psi, about 105.2 psi to about 116 psi, about 108.8 psi to about 112.4 psi, about 108.8 psi to about 116 psi, or about 112.4 psi to about 116 psi. In some embodiments, an extruder operates at an air pressure of about 60 psi, about 87 psi, about 90.6 psi, about 94.3 psi, about 97.9 psi, about 100 psi, about 101.5 psi, about 104 psi, about 105.2 psi, about 108.8 psi, about 112.4 psi, about 116 psi, or about 120 psi. In some embodiments, an extruder operates at an air pressure of at least about 60 psi, at least about 87 psi, at least about 90.6 psi, at least about 94.3 psi, at least about 97.9 psi, at least about 101.5 psi, at least about 105.2 psi, at least about 108.8 psi, or at least about 112.4 psi. In some embodiments, an extruder operates at an air pressure of at most about 90.6 psi, atWSGR Docket No. 56745-707.601most about 94.3 psi, at most about 97.9 psi, at most about 101.5 psi, at most about 105.2 psi, at most about 108.8 psi, at most about 112.4 psi, at most about 116 psi, or at most about 120 psi.

[0164] A method of the disclosure can comprise printing a material at various linear extrusion speeds. In some embodiments, material may be deposited at a linear extrusion speed of about 2 mm / s to about 800 millimeters per second (mm / s). In some embodiments, material may be deposited at a linear extrusion speed of about 100 mm / s to about 150 mm / s, about 100 mm / s to about 200 mm / s, about 100 mm / s to about 250 mm / s, about 100 mm / s to about 300 mm / s, about 100 mm / s to about 350 mm / s, about 100 mm / s to about 400 mm / s, about 100 mm / s to about 450 mm / s, about 100 mm / s to about 500 mm / s, about 100 mm / s to about 600 mm / s, about 100 mm / s to about 700 mm / s, about 100 mm / s to about 800 mm / s, about 150 mm / s to about 200 mm / s, about 150 mm / s to about 250 mm / s, about 150 mm / s to about 300 mm / s, about 150 mm / s to about 350 mm / s, about 150 mm / s to about 400 mm / s, about 150 mm / s to about 450 mm / s, about 150 mm / s to about 500 mm / s, about 150 mm / s to about 600 mm / s, about 150 mm / s to about 700 mm / s, about 150 mm / s to about 800 mm / s, about 200 mm / s to about 250 mm / s, about 200 mm / s to about 300 mm / s, about 200 mm / s to about 350 mm / s, about 200 mm / s to about 400 mm / s, about 200 mm / s to about 450 mm / s, about 200 mm / s to about 500 mm / s, about 200 mm / s to about 600 mm / s, about 200 mm / s to about 700 mm / s, about 200 mm / s to about 800 mm / s, about 250 mm / s to about 300 mm / s, about 250 mm / s to about 350 mm / s, about 250 mm / s to about 400 mm / s, about 250 mm / s to about 450 mm / s, about 250 mm / s to about 500 mm / s, about 250 mm / s to about 600 mm / s, about 250 mm / s to about 700 mm / s, about 250 mm / s to about 800 mm / s, about 300 mm / s to about 350 mm / s, about 300 mm / s to about 400 mm / s, about 300 mm / s to about 450 mm / s, about 300 mm / s to about 500 mm / s, about 300 mm / s to about 600 mm / s, about 300 mm / s to about 700 mm / s, about 300 mm / s to about 800 mm / s, about 350 mm / s to about 400 mm / s, about 350 mm / s to about 450 mm / s, about 350 mm / s to about 500 mm / s, about 350 mm / s to about 600 mm / s, about 350 mm / s to about 700 mm / s, about 350 mm / s to about 800 mm / s, about 400 mm / s to about 450 mm / s, about 400 mm / s to about 500 mm / s, about 400 mm / s to about 600 mm / s, about 400 mm / s to about 700 mm / s, about 400 mm / s to about 800 mm / s, about 450 mm / s to about 500 mm / s, about 450 mm / s to about 600 mm / s, about 450 mm / s to about 700 mm / s, about 450 mm / s to about 800 mm / s, about 500 mm / s to about 600 mm / s, about 500 mm / s to about 700 mm / s, about 500 mm / s to about 800 mm / s, about 600 mm / s to about 700 mm / s, about 600 mm / s to about 800 mm / s, or about 700 mm / s to about 800 mm / s. In some embodiments, the material may be deposited at a linear extrusion speed of about 2WSGR Docket No. 56745-707.601mm / s, about 8 mm / s, about 10 mm / s, about 100 mm / s, about 150 mm / s, about 200 mm / s, about 250 mm / s, about 300 mm / s, about 350 mm / s, about 400 mm / s, about 450 mm / s, about 500 mm / s, about 600 mm / s, about 700 mm / s, or about 800 mm / s. In some embodiments, the material may be deposited at a linear extrusion speed of at least about 2 mm / s, at least about 8 mm / s, at least about 10 mm / s, at least about 50 mm / s, at least about 100 mm / s, at least about 150 mm / s, at least about 200 mm / s, at least about 250 mm / s, at least about 300 mm / s, at least about 350 mm / s, at least about 400 mm / s, at least about 450 mm / s, at least about 500 mm / s, at least about 600 mm / s, or at least about 700 mm / s. In some embodiments, the material may be deposited at a linear extrusion speed of at most about 150 mm / s, at most about 200 mm / s, at most about 250 mm / s, at most about 300 mm / s, at most about 350 mm / s, at most about 400 mm / s, at most about 450 mm / s, at most about 500 mm / s, at most about 600 mm / s, at most about 700 mm / s, or at most about 800 mm / s.

[0165] A method of the disclosure can comprise printing a material at various volumetric speeds. In some embodiments, the printing occurs with a volumetric speed of about 1 microliters per second (pL / s) to about 100 pL / s. In some embodiments, the printing occurs with a volumetric speed of about 1 pL / s to about 5 pL / s, about 1 pL / s to about 10 pL / s, about 1 pL / s to about 15 pL / s, about 1 pL / s to about 20 pL / s, about 1 pL / s to about 25 pL / s, about 1 pL / s to about 50 pL / s, about 1 pL / s to about 100 pL / s, about 5 pL / s to about 10 pL / s, about 5 pL / s to about 15 pL / s, about 5 pL / s to about 20 pL / s, about 5 pL / s to about 25 pL / s, about 5 pL / s to about 50 pL / s, about 5 pL / s to about 100 pL / s, about 10 pL / s to about 15 pL / s, about 10 pL / s to about 20 pL / s, about 10 pL / s to about 25 pL / s, about 10 pL / s to about 50 pL / s, about 10 pL / s to about 100 pL / s, about 15 pL / s to about 20 pL / s, about 15 pL / s to about 25 pL / s, about 15 pL / s to about 50 pL / s, about 15 pL / s to about 100 pL / s, about 20 pL / s to about 25 pL / s, about 20 pL / s to about 50 pL / s, about 20 pL / s to about 100 pL / s, about 25 pL / s to about 50 pL / s, about 25 pL / s to about 100 pL / s, or about 50 pL / s to about 100 pL / s. In some embodiments, the printing occurs with a volumetric speed of about 1 pL / s, about 5 pL / s, about 10 pL / s, about 15 pL / s, about 20 pL / s, about 25 pL / s, about 50 pL / s, or about 100 pL / s. In some embodiments, the printing occurs with a volumetric speed of at least about 1 pL / s, at least about 5 pL / s, at least about 10 pL / s, at least about 15 pL / s, at least about 20 pL / s, at least about 25 pL / s, or at least about 50 pL / s. In some embodiments, the printing occurs with a volumetric speed of at most about 5 pL / s, at most about 10 pL / s, at most about 15 pL / s, at most about 20 pL / s, at most about 25 pL / s, at most about 50 pL / s, or at most about 100 pL / s.WSGR Docket No. 56745-707.601

[0166] A method of the disclosure can comprise controlling the deposition of materials (e.g. polymers) with a degree of resolution. In some embodiments, a method disclosed herein can control material deposition with a resolution of about 0.01 mm to about 1 mm. In some embodiments, a method disclosed herein can control material deposition with a resolution of about 0.01 mm to about 0.05 mm, about 0.01 mm to about 0.1 mm, about 0.01 mm to about 0.2 mm, about 0.01 mm to about 0.3 mm, about 0.01 mm to about 0.4 mm, about 0.01 mm to about 0.5 mm, about 0.01 mm to about 1 mm, about 0.05 mm to about 0.1 mm, about 0.05 mm to about 0.2 mm, about 0.05 mm to about 0.3 mm, about 0.05 mm to about 0.4 mm, about 0.05 mm to about 0.5 mm, about 0.05 mm to about 1 mm, about 0.1 mm to about 0.2 mm, about 0.1 mm to about 0.3 mm, about 0.1 mm to about 0.4 mm, about 0.1 mm to about 0.5 mm, about 0.1 mm to about 1 mm, about 0.2 mm to about 0.3 mm, about 0.2 mm to about 0.4 mm, about 0.2 mm to about 0.5 mm, about 0.2 mm to about 1 mm, about 0.3 mm to about 0.4 mm, about 0.3 mm to about 0.5 mm, about 0.3 mm to about 1 mm, about 0.4 mm to about 0.5 mm, about 0.4 mm to about 1 mm, or about 0.5 mm to about 1 mm. In some embodiments, a method disclosed herein can control material deposition with a resolution of about 0.01 mm, about 0.05 mm, about 0.1 mm, about 0.2 mm, about 0.3 mm, about 0.4 mm, about 0.5 mm, or about 1 mm. In some embodiments, a method disclosed herein can control material deposition with a resolution of at least about 0.01 mm, at least about 0.05 mm, at least about 0.1 mm, at least about 0.2 mm, at least about 0.3 mm, at least about 0.4 mm, or at least about 0.5 mm. In some embodiments, a method disclosed herein can control material deposition with a resolution of at most about 0.05 mm, at most about 0.1 mm, at most about 0.2 mm, at most about 0.3 mm, at most about 0.4 mm, at most about 0.5 mm, or at most about 1 mm.Computer system

[0167] In some embodiments, the present disclosure provides a non-transitory computer readable medium comprising machine executable code that, upon execution by one or more computer processors, implements any of the methods above or elsewhere herein, e.g., 3D printing the biomaterial.

[0168] In some embodiments, the present disclosure provides a system comprising one or more computer processors and computer memory coupled thereto. The computer memory comprises machine executable code that, upon execution by the one or more computer processors, implements any of the methods above or elsewhere herein.WSGR Docket No. 56745-707.601

[0169] In some embodiments, the present disclosure provides computer systems that are programmed to implement methods of the disclosure. FIG. 17 shows a computer system 1801 that is programmed or otherwise configured to communicate with and regulate various aspects of the present disclosure. The computer system 1801 can regulate various operations of the 3D printer. The computer system 1801 can be an electronic device of a user or a computer system that is remotely located with respect to the electronic device. The electronic device can be a mobile electronic device.

[0170] The computer system 1801 includes a central processing unit (CPU, also “processor” and “computer processor” herein) 1805, which can be a single core or multi core processor, or a plurality of processors for parallel processing. The computer system 1801 also includes memory or memory location 1810 (e.g., random-access memory, read-only memory, flash memory), electronic storage unit 1815 (e.g., hard disk), communication interface 1820 (e.g., network adapter) for communicating with one or more other systems, and peripheral devices 1825, such as cache, other memory, data storage and / or electronic display adapters. The memory 1810, storage unit 1815, interface 1820 and peripheral devices 1825 are in communication with the CPU 1805 through a communication bus (solid lines), such as a motherboard. The storage unit 1815 can be a data storage unit (or data repository) for storing data. The computer system 1801 can be operatively coupled to a computer network (“network”) 1830 with the aid of the communication interface 1820. The network 1830 can be the Internet, an internet and / or extranet, or an intranet and / or extranet that is in communication with the Internet. The network 1830 in some cases is a telecommunication and / or data network. The network 1830 can include one or more computer servers, which can enable distributed computing, such as cloud computing. The network 1830, in some cases with the aid of the computer system 1801, can implement a peer-to-peer network, which can enable devices coupled to the computer system 1801 to behave as a client or a server.

[0171] The CPU 1805 can execute a sequence of machine-readable instructions, which can be embodied in a program or software. The instructions can be stored in a memory location, such as the memory 1810. The instructions can be directed to the CPU 1805, which can subsequently program or otherwise configure the CPU 1805 to implement methods of the present disclosure. Examples of operations performed by the CPU 1805 can include fetch, decode, execute, and writeback.WSGR Docket No. 56745-707.601

[0172] The CPU 1805 can be part of a circuit, such as an integrated circuit. One or more other components of the system 1801 can be included in the circuit. In some cases, the circuit is an application specific integrated circuit (ASIC).

[0173] The storage unit 1815 can store files, such as drivers, libraries and saved programs. The storage unit 1815 can store user data, e.g., user preferences and user programs. The computer system 1801 in some cases can include one or more additional data storage units that are external to the computer system 1801, such as located on a remote server that is in communication with the computer system 1801 through an intranet or the Internet.

[0174] The computer system 1801 can communicate with one or more remote computer systems through the network 1830. For instance, the computer system 1801 can communicate with a remote computer system of a user. Examples of remote computer systems include personal computers (e.g., portable PC), slate or tablet PC’s (e.g., Apple® iPad, Samsung® Galaxy Tab), telephones, Smart phones (e.g., Apple® iPhone, Android-enabled device, Blackberry®), or personal digital assistants. The user can access the computer system 1801 via the network 1830.

[0175] Methods as described herein can be implemented by way of machine (e.g., computer processor) executable code stored on an electronic storage location of the computer system 1801, such as, for example, on the memory 1810 or electronic storage unit 1815. The machine executable or machine readable code can be provided in the form of software.During use, the code can be executed by the processor 1805. In some cases, the code can be retrieved from the storage unit 1815 and stored on the memory 1810 for ready access by the processor 1805. In some situations, the electronic storage unit 1815 can be precluded, and machine-executable instructions are stored on memory 1810.

[0176] The code can be pre-compiled and configured for use with a machine having a processer adapted to execute the code, or can be compiled during runtime. The code can be supplied in a programming language that can be selected to enable the code to execute in a pre-compiled or as-compiled fashion.

[0177] Aspects of the systems and methods provided herein, such as the computer system 1801, can be embodied in programming. Various aspects of the technology can be thought of as “products” or “articles of manufacture” typically in the form of machine (or processor) executable code and / or associated data that is carried on or embodied in a type of machine readable medium. Machine-executable code can be stored on an electronic storage unit, such as memory (e.g., read-only memory, random-access memory, flash memory) or a hard disk. “Storage” type media can include any or all of the tangible memory of the computers,WSGR Docket No. 56745-707.601processors or the like, or associated modules thereof, such as various semiconductor memories, tape drives, disk drives and the like, which can provide non-transitory storage at any time for the software programming. All or portions of the software can at times be communicated through the Internet or various other telecommunication networks. Such communications, for example, can enable loading of the software from one computer or processor into another, for example, from a management server or host computer into the computer platform of an application server. Thus, another type of media that can bear the software elements includes optical, electrical and electromagnetic waves, such as used across physical interfaces between local devices, through wired and optical landline networks and over various air-links. The physical elements that carry such waves, such as wired or wireless links, optical links or the like, also can be considered as media bearing the software. As used herein, unless restricted to non-transitory, tangible “storage” media, terms such as computer or machine “readable medium” refer to any medium that participates in providing instructions to a processor for execution.

[0178] Hence, a machine readable medium, such as computer-executable code, can take many forms, including but not limited to, a tangible storage medium, a carrier wave medium or physical transmission medium. Non-volatile storage media include, for example, optical or magnetic disks, such as any of the storage devices in any computer(s) or the like, such as can be used to implement the databases, etc. shown in the drawings. Volatile storage media include dynamic memory, such as main memory of such a computer platform. Tangible transmission media include coaxial cables; copper wire and fiber optics, including the wires that comprise a bus within a computer system. Carrier-wave transmission media can take the form of electric or electromagnetic signals, or acoustic or light waves such as those generated during radio frequency (RF) and infrared (IR) data communications. Common forms of computer-readable media therefore include for example: a floppy disk, a flexible disk, hard disk, magnetic tape, any other magnetic medium, a CD-ROM, DVD or DVD-ROM, any other optical medium, punch cards paper tape, any other physical storage medium with patterns of holes, a RAM, a ROM, a PROM and EPROM, a FLASH-EPROM, any other memory chip or cartridge, a carrier wave transporting data or instructions, cables or links transporting such a carrier wave, or any other medium from which a computer can read programming code and / or data. Many of these forms of computer readable media can be involved in carrying one or more sequences of one or more instructions to a processor for execution.WSGR Docket No. 56745-707.601

[0179] The computer system 1801 can include or be in communication with an electronic display 1835 that comprises a user interface (UI) 1840 for providing, for example, deposition speed, extruder pressure, extruder temperature, extruder deposition patterns, the location of deposition, layer thickness, and the material deposited. Examples of UI’s include, without limitation, a graphical user interface (GUI) and web-based user interface.

[0180] Methods and systems of the present disclosure can be implemented by way of one or more algorithms. An algorithm can be implemented by way of software upon execution by the central processing unit 1805. The algorithm can, for example, determine the optimized extruder temperature or printing temperature.Methods of use

[0181] The biomaterials described herein can provide methods for the controlled and prolonged release of one or more therapeutic agents in situ at a target site in the body of a subject in need of treatment of a disease, disorder, or condition treatable by the one or more therapeutic agents. Release of the one or more therapeutic agents from the implanted article can occur through several mechanisms, including but not limited to diffusion through the polymer material, by transport through fluid-filled pores or channels in the polymer material, and through degradation of the polymer material.

[0182] In an aspect, the present disclosure provides a method of treating or preventing a disease or condition. In some embodiments, the method may comprise implanting into a subject one or more delivery articles (or one or more biomaterials). In some embodiments, a delivery article of the one or more delivery articles may comprise a plurality of geometric elements. In some embodiments, the delivery article may comprise a polymer and an active agent. In some embodiments, when administered to a subject, the one or more delivery articles delivers the active agent to a target tissue or region.

[0183] In another aspect, the present disclosure provides one or more delivery articles (or one or more biomaterials) for use in treating or preventing a disease or condition of a subject. The use may comprise implanting into the subject the one or more delivery articles. In some embodiments, a delivery article of the one or more delivery articles may comprise a plurality of geometric elements. In some embodiments, the delivery article may comprise a polymer and an active agent. In some embodiments, when administered to a subject, the one or more delivery articles delivers the active agent to a target tissue or region.

[0184] In another aspect, the present disclosure provides use of one or mor delivery articles (or one or more biomaterials) in the manufacture of a medicament for treating or preventing aWSGR Docket No. 56745-707.601disease or condition of a subject. In some embodiments, the one or more delivery articles are to be implanted into the subject. In some embodiments, a delivery article of the one or more delivery articles may comprise a plurality of geometric elements. In some embodiments, the delivery article may comprise a polymer and an active agent. In some embodiments, when administered to a subject, the one or more delivery articles delivers the active agent to a target tissue or region.

[0185] As provided herein, a target tissue may refer to a specific biological material type (e.g., cartilage, bone, muscle, nerve, skin, etc.) or a specific organ type (e.g., kidney, lung, blood, etc.), a region (or target region) as provided herein may refer to a general anatomical location or area in the body, which may contain or multiple tissue types.

[0186] In some embodiments, a concentration of the active agent is higher in the target tissue or region than a non-targeted tissue or region. In some embodiments, an amount of the active agent delivered to the target tissue or region is ascertained by plasma bioanalysis, e.g., via Liquid Chromatography-Tandem Mass Spectrometry (LC-MS / MS), High-Performance Liquid Chromatography (HPLC), or both.

[0187] In another aspect, the present disclosure provides a method of preferentially delivering an active agent to a target tissue or region of a subject to treat or prevent a disease or condition. In some embodiments, the method may comprise implanting into the subject one or more delivery articles. In some embodiments, a delivery article of the one or more delivery articles may comprise a plurality of geometric elements. In some embodiments, the delivery article may comprise a polymer and an active agent. In some embodiments, a concentration of the active agent is higher in the target tissue or region than a non-targeted tissue or region. In some embodiments, the concentration of the active agent is measured via tissue bioanalysis, e.g., Liquid Chromatography-Tandem Mass Spectrometry (LC-MS / MS), High-Performance Liquid Chromatography (HPLC), or both. In some embodiments, an amount of the active agent released or moved to the non-target tissue or region is ascertained by the tissue bioanalysis or plasma bioanalysis, e.g., via Liquid Chromatography-Tandem Mass Spectrometry (LC-MS / MS), High-Performance Liquid Chromatography (HPLC), or both.

[0188] As used herein, the term “preferential” or “preferentially,” when used in the context of release and / or delivery of the active agent from the biomaterial to the target tissue or region, generally refers to a greater degree of drug accumulation, retention, or release at a target tissue or region relative to non-target tissues or region, organs, or systemic circulation. Preferential delivery does not require exclusive delivery to the target tissue or region, butWSGR Docket No. 56745-707.601rather that the target tissue or region receives a greater concentration or bioavailable fraction of the active agent compared to non-target sites or regions and / or a faster delivery of the active agent compared to non-target tissue or region.

[0189] In some embodiments, the concentration of the active agent is at least 2-fold, at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, at least 100-fold, at least 200-fold, or at least 500-fold higher in the target tissue or region than in the non-target tissue or region. In some embodiments, the non-target tissue or region is liver or blood vessel (or plasma). In some embodiments, the target tissue or region may comprise colorectal site, peritoneal site, or mesentery site. In some embodiments, the target tissue or region may comprise the colorectal site. In some embodiments, the colorectal site may comprise intraluminal site or serosa of bowel. In some embodiments, the concentration of the active agent is at least 2-fold, at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, at least 100-fold, at least 200-fold, or at least 500-fold higher in the colorectal site than that in the blood vessel (or plasma); and / or at least 2-fold, at least 5-fold, at least 10-fold, at least 20-fold, or at least 40-fold higher in the colorectal site than that in the liver. In some embodiments, the target tissue or region may comprise the peritoneal site. In some embodiments, the peritoneal site may comprise peritoneal wall, left peritoneal cavity, or right peritoneal cavity. In some embodiments, the concentration of the active agent is at least 2-fold, at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, at least 100-fold, or at least 200-fold higher in the peritoneal site than that in the blood vessel (or plasma); and / or at least 2-fold, at least 5-fold, at least 10-fold, or at least 15-fold higher in the peritoneal site than that in the liver. In some embodiments, the target tissue or region may comprise the mesentery site. In some embodiments, the concentration of the active agent is at least 2-fold, at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, at least 100-fold, or at least 200-fold higher in the mesentery site than that in the blood vessel (or plasma); and / or at least 2-fold, at least 5-fold, at least 10-fold, or at least 15-fold higher in the mesentery site than that in the liver.

[0190] In some embodiments, the active agent may be released locally at or near the site of implantation. In some embodiments, the active agent is substantially not released to the systemic circulation. In some embodiments, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 9%, less than about 8%, less than about 7%, less than about 6%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, less than about 1%, less than about 0.5%, less than about 0.2%, or less than about 0.1% of the active agent pre-loaded to the biomaterial may be released to the systemic circulation, to the liver, or both.WSGR Docket No. 56745-707.601

[0191] In some embodiments, the active agent may be released locally at or near the site of implantation with or to a level of 100 nanograms of the active agent per gram of a tissue having had contact or being directly adjacent to the biomaterial (ng / g) to 5000 ng / g, from about 100 ng / g to about 500 ng / g, from about 100 ng / g to about 1000 ng / g, from about 100 ng / g to about 2000 ng / g, from about 200 ng / g to about 800 ng / g, from about 200 ng / g to about 1500 ng / g, from about 250 ng / g to about 750 ng / g, from about 250 ng / g to about 2500 ng / g, from about 300 ng / g to about 1000 ng / g, from about 300 ng / g to about 3000 ng / g, from about 500 ng / g to about 1500 ng / g, from about 500 ng / g to about 2500 ng / g, from about 500 ng / g to about 5000 ng / g, from about 750 ng / g to about 2000 ng / g, from about 750 ng / g to about 3500 ng / g, from about 1000 ng / g to about 2000 ng / g, from about 1000 ng / g to about 3000 ng / g, from about 1000 ng / g to about 5000 ng / g, from about 1500 ng / g to about 3500 ng / g, from about 2000 ng / g to about 4000 ng / g, or from about 2500 ng / g to about 5000 ng / g. In some embodiments, comparatively, the active agent may be released systemically (e.g., to the blood vessel or plasma) with or to a level in plasma below 50 nanograms of the active agent per milliliters of plasma (ng / mL), below 40 ng / mL, below 30 ng / mL, below 20 ng / mL, below 15 ng / mL, or below 10 ng / mL.

[0192] Several structural features of a biomaterial disclosed herein can be adapted to modify the release of therapeutic agent(s) from the biomaterial. These structural features include but are not limited to the composition of the polymer material, the density and / or porosity of the polymer material, the sub-structure of the unit biomaterials (e.g. in a layered biomaterial) formed by the defined pattern of geometric elements, including the size, shape, and the number and arrangement of filled and open geometric elements.

[0193] The macro three-dimensional configuration of a biomaterial of the disclosure can also be adapted to modify release of therapeutic agent(s) and / or to focus release to a particular portion or region of the article. For example, a biomaterial can be folded or rolled for insertion into a target site (target tissue or region). Several unit biomaterials can also be formed or printed into stacked layers having a desired orientation, including a staggered configuration. In some embodiments, the article can be coated with a coating. In some embodiments, the coating prevents a burst release upon placement of the biomaterial in situ. For example, the biomaterial can be coated with the same drug using a dip-coat method which is a standard method used in medicinal research and drug development. Dip coating of an article can be achieved by dipping the biomaterial into a polymer-drug solution and then drying the biomaterial to create a thin, uniform coating. Alternatively, a spray can be used to coat the biomaterial, which can allow for direct spraying of micro-droplets of a therapeuticWSGR Docket No. 56745-707.601agent onto the biomaterial itself. In some embodiments, a combination of the above can be used to coat the biomaterial using a hybrid method.

[0194] In some embodiments, a biomaterial releases one or more therapeutic agents over a period of time from about 1 day to about 1 week, about 1 week to about 1 month, about 1 month to about 2 months, about 2 months to about 6 months, about 6 months to about 12 months, about 12 months to about 24 months, about 24 months to about 42 months, about 24 months to about 54 months, or from about 24 months to about 60 months. In some embodiments, a biomaterial releases a therapeutic agent or agents over a period of time of about 24 months, about 30 months, about 36 months, about 42 months, about 54 months, or about 60 months. In some embodiments, a biomaterial releases a therapeutic agent or agents over a period of time of at least about 24 months, at least about 30 months, at least about 36 months, at least about 42 months, at least about 54 months, or at least about 60 months. In some embodiments, a biomaterial releases a therapeutic agent or agents over a period of time of at most about 24 months, at most about 30 months, at most about 36 months, at most about 42 months, at most about 54 months, or at most about 60 months.

[0195] Non-limiting examples of a subject include a human, primate, mouse, rat, dog, cat, cow, horse, goat, camel, sheep or a pig. In some embodiments, methods disclosed herein are methods of treating a subject in need thereof.

[0196] In some embodiments, a therapeutically effective amount of the one or more therapeutic agents can delivered to the in situ target site (target tissue or region) over a period of time, through implantation of a biomaterial of the disclosure.

[0197] Methods disclosed herein can treat conditions by, for example, alleviating, reducing, or reducing the likelihood of one or more symptoms or complications of a disease or disorder. In some embodiments, a method disclosed herein reduces the likelihood of a disease or disorder occurring in a subject. For example, in the context of cancer, treating the cancer can include slowing the growth of the cancer, slowing or preventing the occurrence of metastases, or further metastases, and promoting regression of one or more tumors in the subject being treated.

[0198] In some embodiments, the biomaterial is for use in releasing a drug over a period of, for example, about 3 weeks, about 4 weeks, about 30 days, or about 5 weeks. Within the period, an amount of drug can be released from the biomaterial, for example, about 40% (e.g., + / -10%), 50% (e.g., + / -10%), 55% (e.g., + / -10%), 60% (e.g., + / -10%), 65% (e.g., + / -10%), 70% (e.g., + / -10%), 75% (e.g., + / -10%), 80% (e.g., + / -10%), or 85% (e.g., + / -10%).WSGR Docket No. 56745-707.601For example, approximately 75% of a 20mg dose of 5-FU can be released, delivering a therapeutic dose of 15 mg.

[0199] In some embodiments, the biomaterial releases about 40% (e.g., + / - 10%), about 50% (e.g., + / -10%), about 55% (e.g., + / -10%), about 60% (e.g., + / -10%), about 65% (e.g., + / -10%), about 70% (e.g., + / -10%), about 75% (e.g., + / -10%), about 80% (e.g., + / -10%), or about 85% (e.g., + / - 10%) of a drug over a period of three weeks. In some embodiments, the biomaterial releases about 40% (e.g., + / - 10%), about 50% (e.g., + / - 10%), about 55% (e.g., + / -10%), about 60% (e.g., + / -10%), about 65% (e.g., + / -10%), about 70% (e.g., + / -10%), about 75% (e.g., + / -10%), about 80% (e.g., + / -10%), or about 85% (e.g., + / -10%) of a drug over a period of four weeks. In some embodiments, the biomaterial releases about 40% (e.g., + / -10%), about 50% (e.g., + / -10%), about 55% (e.g., + / -10%), about 60% (e.g., + / -10%), about 65% (e.g., + / -10%), about 70% (e.g., + / -10%), about 75% (e.g., + / -10%), about 80% (e.g., + / -10%), or about 85% (e.g., + / -10%) of a drug over a period of five weeks. In some embodiments, the biomaterial releases about 40% (e.g., + / - 10%), about 50% (e.g., + / - 10%), about 55% (e.g., + / -10%), about 60% (e.g., + / -10%), about 65% (e.g., + / -10%), about 70% (e.g., + / -10%), about 75% (e.g., + / -10%), about 80% (e.g., + / -10%), or about 85% (e.g., + / -10%) of a drug over a period of 30 days.

[0200] In some embodiments, the biomaterial releases at least about 40% (e.g., + / - 10%), at least about 50% (e.g., + / - 10%), at least about 55% (e.g., + / - 10%), at least about 60% (e.g., + / -10%), at least about 65% (e.g., + / - 10%), at least about 70% (e.g., + / -10%), at least about 75% (e.g., + / - 10%), at least about 80% (e.g., + / -10%), or at least about 85% (e.g., + / - 10%) of a drug over a period of three weeks. In some embodiments, the biomaterial releases at least about 40% (e.g., + / -10%), at least about 50% (e.g., + / -10%), at least about 55% (e.g., + / -10%), at least about 60% (e.g., + / - 10%), at least about 65% (e.g., + / -10%), at least about 70% (e.g., + / -10%), at least about 75% (e.g., + / -10%), at least about 80% (e.g., + / - 10%), or at least about 85% (e.g., + / - 10%) of a drug over a period of four weeks. In some embodiments, the biomaterial releases at least about 40% (e.g., + / -10%), at least about 50% (e.g., + / -10%), at least about 55% (e.g., + / - 10%), at least about 60% (e.g., + / - 10%), at least about 65% (e.g., + / -10%), at least about 70% (e.g., + / - 10%), at least about 75% (e.g., + / -10%), at least about 80% (e.g., + / - 10%), or at least about 85% (e.g., + / -10%) of a drug over a period of five weeks. In some embodiments, the biomaterial releases at least about 40% (e.g., + / - 10%), at least about 50% (e.g., + / -10%), at least about 55% (e.g., + / -10%), at least about 60% (e.g., + / -10%), at least about 65% (e.g., + / - 10%), at least about 70% (e.g., + / - 10%), at least about 75% (e.g., + / -WSGR Docket No. 56745-707.60110%), at least about 80% (e.g., + / - 10%), or at least about 85% (e.g., + / - 10%) of a drug over a period of 30 days.

[0201] In some embodiments, a single dose may be administered. For example, the one or more biomaterials are administered, and optionally removed, e.g., four weeks after implant. In some embodiments, repeat doses are administered. For example, the one or more biomaterials are administered, and optionally removed (e.g., four weeks after implant), then one or more biomaterials are administered a second time (e.g., about 30 days after the first dosage). In some embodiments, repeat doses are administered, for example, about every four weeks (e.g., + / -5 days), about every 30 days (e.g., + / -5 days), about every 45 days (e.g., + / -5 days), or about every 60 days (e.g., + / -5 days).

[0202] In some embodiments, a biomaterial may comprise a dose of drug disclosed herein (e.g., an active pharmaceutical ingredient (API), such as 5-FU), that is about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 40 mg, about 60 mg, about 80 mg, about 100 mg, about 120 mg, about 140 mg, about 160 mg, or about 180 mg. In some embodiments, a biomaterial may comprise a dose of drug that is about 10-180 mg, about 20-180 mg. about 20-100 mg, about 10-60 mg, about 20-60 mg, about 20-40 mg or about 15-30 mg. In some embodiments, a biomaterial may comprise a dose of drug that is at least about 10 mg, at least about 15 mg, at least about 20 mg, at least about 25 mg, at least about 30 mg, at least about 40 mg, at least about 60 mg, at least about 80 mg, at least about 100 mg, at least about 120 mg, at least about 140 mg, at least about 160 mg, or at least about 180 mg. In some embodiments, a biomaterial may comprise a dose of drug that is at most about 10 mg, at most about 15 mg, at most about 20 mg, at most about 25 mg, at most about 30 mg, at most about 40 mg, at most about 60 mg, at most about 80 mg, at most about 100 mg, at most about 120 mg, at most about 140 mg, at most about 160 mg, or at most about 180 mg. In some embodiments, the biomaterial may comprise the dose in one biomaterial unit (e.g., chip) disclosed herein. In some embodiments, the dose is divided between two, three, four, or five biomaterial units (e.g., chips). The multiple units can be separate or can be joined (e.g., sutured, stapled, clipped, press-fitted, bio-glued, laser-welded, cross-linked, etc. at one or more corners) together. The multiple units can be joined prior to being implanted to a target site (e.g., a tumor site). Alternatively or in addition to, the multiple units can be joined at the target site, e.g., via one or more endoscopic procedures.

[0203] A biomaterial disclosed herein can limit systemic exposure to a therapeutic agent (e.g., drug). In some embodiments, a level of a drug in circulation (e.g., blood or plasma) of a subject with a biomaterial locally applied is at most 25%, at most 20%, at most 15%, at mostWSGR Docket No. 56745-707.60110%, at most 5%, or at most 1% of a level in a subject administered the therapeutic agent by a systemic route (e.g., intravenously). A biomaterial disclosed herein can limit systemic exposure to a therapeutic agent (e.g., drug). In some embodiments, a level of a drug in circulation (e.g., blood or plasma) of a subject with a biomaterial locally applied is at most 50%, at most 25%, at most 20%, at most 15%, at most 10%, at most 5%, or at most 1% of a level in a subject administered the therapeutic agent topically.

[0204] In some embodiments, the biomaterial comprising a therapeutic agent as provided herein may limit or reduce systemic exposure to the therapeutic agent, e.g., upon implanting the biomaterial to a local site of a subject (e.g., a human subject). In some cases, a level of a therapeutic agent in circulation (e.g., blood or plasma) of a subject with a biomaterial locally applied may be at most 50%, at most 25%, at most 20%, at most 15%, at most 10%, at most 5%, or at most 1% of a level in a subject administered the active agent topically or systemically.Methods of treating cancer

[0205] The present disclosure provides methods of treating cancer in a subject in need thereof, the methods comprising implanting a biomaterial of the disclosure into a target site of the subject. In some embodiments, the target site may be a portion of an organ, hard tissue, soft tissue, or lymph node. In some embodiments, the target site may comprise a solid tumor or portion thereof. The surgical article can be loaded with an amount of one or more therapeutic agents effective to provide a therapeutic dose of the one or more agents to the target site in situ for a period of time ranging from weeks, to months, to years, as described supra.

[0206] In some embodiments, the biomaterial may be placed (e.g., implanted) at or adjacent to a solid tumor site or a tissue having the solid tumor. Once placed, the distance between the biomaterial (e.g., a central position or an edge of the biomaterial) and the target solid tumor site or target tissue site may be at least about 0.1 cm, at least about 0.2 cm, at least about 0.5 cm, at least about 1 cm, at least about 2 cm, at least about 5 cm; and / or at most about 5 cm, at most about 2 cm, at most about 1 cm, at most about 0.5 cm, at most about 0.2 cm, or at most about 0.1 cm. In some embodiments, the biomaterial may be placed over a tissue site, e.g., over a target tumor site. At least a portion of the biomaterial in contact with the tissue site (or covering at least a portion of the tissue site) may be at least is at least 1%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, atWSGR Docket No. 56745-707.601least 80%, at least 85%, at least 90%, at least 95%, or substantially 100% of a surface of the biomaterial in contact with the tissue site; and / or at most 1%, at most 5%, at most 10%, at most 15%, at most 20%, at most 25%, at most 30%, at most 35%, at most 40%, at most 45%, at most 50%, at most 55%, at most 60%, at most 65%, at most 70%, at most 75%, at most 80%, at most 85%, at most 90%, at most 95%, or substantially up to 100% of the surface of the biomaterial in contact with the tissue site. The at least the portion of the tissue site that is covered by the at least the portion of the biomaterial may be at least is at least 1%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or substantially 100% of a surface of the tissue site; and / or at most 1%, at most 5%, at most 10%, at most 15%, at most 20%, at most 25%, at most 30%, at most 35%, at most 40%, at most 45%, at most 50%, at most 55%, at most 60%, at most 65%, at most 70%, at most 75%, at most 80%, at most 85%, at most 90%, at most 95%, or substantially up to 100% of the surface of the tissue site.

[0207] In some embodiments, the subject in need of treatment may be a human patient diagnosed with a cancer, for example, colorectal cancer, anal cancer, esophageal cancer, gastric cancer, breast cancer, skin cancer, bone cancer, prostate cancer, liver cancer, lung cancer, brain cancer, cancer of the larynx, cancer of the gall bladder, pancreatic cancer, rectal cancer, parathyroid cancer, thyroid cancer, adrenal cancer, neural tissue cancer, head and neck cancer, colon cancer, stomach cancer, cancer of the bronchi, renal cancer, basal cell carcinoma, squamous cell carcinoma of both ulcerating and papillary type, metastatic skin carcinoma, osteosarcoma, Ewing's sarcoma, veticulum cell sarcoma, myeloma, giant cell tumor, small-cell lung tumor, islet cell tumor, primary brain tumor, acute and chronic lymphocytic and granulocytic tumors, hairy-cell tumor, adenoma, hyperplasia, medullary carcinoma, pheochromocytoma, mucosal neuromas, intestinal ganglioneuromas, hyperplastic corneal nerve tumor, marfanoid habitus tumor, Wilm's tumor, seminoma, ovarian tumor, cervical dysplasia and in situ carcinoma, neuroblastoma, retinoblastoma, soft tissue sarcoma, malignant carcinoid, mycosis fungoide, rhabdomyosarcoma, Kaposi's sarcoma, osteogenic and other sarcoma, renal cell tumor, polycythemia vera, adenocarcinoma, glioblastoma multiforma, leukemias, lymphomas, malignant melanomas, epidermoid carcinomas, carcinomas, sarcomas, hemangiomas, hepatocellular adenoma, cavernous hemangioma, focal nodular hyperplasia, acoustic neuromas, neurofibroma, bile duct adenoma, bile duct cystanoma, fibroma, lipomas, leiomyomas, mesotheliomas, teratomas, myxomas, and nodular regenerative hyperplasia.WSGR Docket No. 56745-707.601

[0208] In some embodiments, the cancer may be metastatic. In some embodiments, the cancer may be non-metastatic. In some embodiments, the cancer may be an advanced local cancer. In some embodiments, the cancer may be a recurrent locally advanced cancer.

[0209] In some embodiments, a biomaterial disclosed herein can be used to treat the subject having a malignant cancer or late-stage cancer. In some embodiments, the subject in need of treatment can also be one that is non-responsive or refractory to a currently available therapy, or to the standard of care therapy for the disease, disorder, or condition being treated, such as the cancer.

[0210] In some embodiments, a biomaterial disclosed herein can be used to treat a colorectal cancer, for example, a colon cancer, a rectal cancer, or a bowel cancer, a gastrointestinal malignancy, or any cancer that developed in the colon or rectum. In some embodiments, a biomaterial for treating colon cancer may comprise a therapeutic agent indicated for the treatment of colon cancer. In some embodiments, the biomaterial may comprise a therapeutic agent selected from one or more of gemcitabine (Gemzar), raltitrexed (Tomudex™) oxaliplatin (Eloxatin™), regorafenib, irinotecan (Camptostar™), and 5 -fluorouracil (Adrucil™). In some embodiments, the therapeutic agent may be selected from capecitabine, fluorouracil, irinotecan and oxaliplatin, and combinations thereof.

[0211] In some embodiments, treating cancer according to the methods described herein leads to the elimination of a symptom or complication of the cancer being treated.Elimination of the symptom is not required. In some embodiments, the severity of the symptom is decreased. In the context of cancer, non-limiting examples of such symptoms include clinical markers of severity or progression including the degree to which a tumor secretes growth factors, degrades the extracellular matrix, becomes vascularized, loses adhesion to juxtaposed tissues, or metastasizes, as well as the number of metastases.

[0212] Treating cancer according to the methods described herein can result in a reduction in size of a tumor. A reduction in size of a tumor can also be referred to as tumor regression. In some embodiments, after treatment, tumor size is reduced by at least about 5% relative to the size of the tumor prior to treatment. In some embodiments, tumor size is reduced by at least about 10% after treatment. In some embodiments, tumor size is reduced by at least about 20% after treatment. In some embodiments, tumor size is reduced by at least about 30% after treatment. In some embodiments, tumor size is reduced by at least about 40% after treatment. In some embodiments, tumor size is reduced by at least about 50% after treatment. In some embodiments, tumor size is reduced by at least about 75% after treatment. In some embodiments, the size of a tumor can be measured as a diameter of the tumor.WSGR Docket No. 56745-707.601

[0213] Treating cancer according to the methods described herein can result in a reduction of tumor volume. In some embodiments, after treatment, tumor volume is reduced by at least about 5% relative to the size of the tumor prior to treatment. In some embodiments, tumor volume is reduced by at least about 10% after treatment. In some embodiments, tumor volume is reduced by at least about 20% after treatment. In some embodiments, tumor volume is reduced by at least about 30% after treatment. In some embodiments, tumor volume is reduced by at least about 40% after treatment. In some embodiments, tumor volume is reduced by at least about 50% after treatment. In some embodiments, tumor volume is reduced by at least about 75% after treatment. In some embodiments, tumor volume is reduced by at least about 60% to at least about 90% after treatment.

[0214] Treating cancer according to the methods described herein can result in a decrease in number of tumors. Tumor number can be reduced by, for example, at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, or at least about 75% relative to the number of tumors prior to treatment. Number of tumors can be measured by any reproducible measurement. The number of tumors can be measured by counting tumors visible to the naked eye or at a specified magnification (e.g. 2x, 3x, 4x, 5x, lOx, or 50x magnification).

[0215] Treating cancer according to the methods described herein can result in a decrease in number of metastatic lesions in tissues or organs other than the primary tumor site. Metastatic lesions can be reduced by, for example, at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, or at least about 75% relative to the number of metastatic lesions prior to treatment. Number of metastatic lesions can be measured by any reproducible measurement. The number of tumors can be measured by counting tumors visible to the naked eye or at a specified magnification (e.g. 2x, 3x, 4x, 5x, lOx, or 50x magnification).

[0216] Treating cancer according to the methods described herein can result in an increase in average survival time of a population of treated subjects in comparison to a population receiving carrier alone. An increase in average survival time of a population can be measured by any reproducible methods. An increase in average survival time of a population can be measured, for example, by calculating for a population the average length of survival following initiation of treatment with an active compound (e.g. implantation of a biomaterial loaded with a therapeutic agent). An increase in average survival time of a population can also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with an active compound. In someWSGR Docket No. 56745-707.601embodiments, the average survival time of a population is increased by at least 30 days, at least 60 days, at least 90 days, or at least 120 days.

[0217] Treating cancer according to the methods described herein can result in increase in average survival time of a population of treated subjects in comparison to a population receiving the standard of care therapy. In some embodiments, the average survival time of a population is increased by at least 30 days, at least 60 days, at least 90 days, or at least 120 days. An increase in average survival time of a population can be measured by any reproducible methods. An increase in average survival time of a population can be measured, for example, by calculating for a population the average length of survival following initiation of treatment with an active compound (e.g. implantation of a biomaterial loaded with a therapeutic agent). An increase in average survival time of a population can also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with an active compound.

[0218] Treating cancer according to the methods described herein can result in a decrease in the mortality rate of a population of treated subjects in comparison to a population receiving carrier alone. Treating cancer according to the methods described herein can result in a decrease in the mortality rate of a population of treated subjects in comparison to an untreated population. Treating cancer according to the methods described herein can result in a decrease in the mortality rate of a population of treated subjects in comparison to a population receiving the standard of care therapy. For example, the mortality rate can be decreased by at least about 2%, at least about 5%, at least about 10% or at least about 25%. A decrease in the mortality rate of a population of treated subjects can be measured by any reproducible methods. A decrease in the mortality rate of a population can be measured, for example, by calculating for a population the average number of disease-related deaths per unit time following initiation of treatment with an active compound. A decrease in the mortality rate of a population can also be measured, for example, by calculating for a population the average number of disease-related deaths per unit time following completion of a first round of treatment with an active compound.

[0219] Treating cancer according to the methods described herein can result in a decrease in tumor growth rate. In some embodiments, a method disclosed herein reduces tumor growth rate by at least about 5%, at least about 10%, at least about 30%, at least about 40%, at least about 50%, or at least about 75% relative to number prior to treatment Tumor growth rate can be measured by any reproducible measurement. Tumor growth rate can be measured according to a change in tumor diameter per unit time. In some embodiments, after treatmentWSGR Docket No. 56745-707.601the tumor growth rate can be about zero and is determined to maintain the same size, i.e., has stopped growing.

[0220] Treating a cancer according to the methods described herein can result in a decrease in tumor regrowth. In some embodiments, treatment with a method disclosed herein results in tumor regrowth that is at most about 5%, at most about 10%, at most about 20%, at most about 30%, at most about 40%, at most about 50%, or at most about 75%. Tumor regrowth is measured, for example, by measuring an increase in the diameter of a tumor after a prior tumor shrinkage that followed treatment. A decrease in tumor regrowth is indicated by failure of tumors to reoccur after treatment has stopped.Methods of treating pain

[0221] The disclosure also provides methods of treating or managing pain in a subject in need thereof, the method comprising implanting a biomaterial described here into a target site of the subject. In some embodiments, the target sites are nerves, connective tissue and skeletal muscle and tissue. The biomaterial can be loaded with an amount of the one or more therapeutic agents effective to provide a therapeutically-effective amount of the one or more agents to the target site in situ for a period of time ranging from weeks, to months, to years, as described above. In some embodiments, the subject in need is a human patient in need of treatment for postsurgical pain, peripheral nerve injury, or chronic lower back pain. In some embodiments, the subject is in need of treatment or management of pain associated with osteoarthritis, diabetic peripheral neuropathy or musculoskeletal injury or trauma.

[0222] In some embodiments, for treating pain described herein, one or more therapeutic agents of a biomaterial is an opioid. Non-limiting examples of opioids include morphine, fentanyl, hydromorphone, codeine, oxycodone, hydrocodone, tramadol, methadone, alfentanil, remifentanil, and derivations thereof.

[0223] In some embodiments of the methods for treating pain described herein, the one or more therapeutic agents is dexamethasone, ondansetron, acetaminophen, a nonsteroidal antiinflammatory drug (NSAID), gabapentin, pregabalin, capsaicin, ketamine, memantine, clonidine, dexmedetomidine, tapentadol, transdermal fentanyl, a long acting local anesthetic, a cannabinoid, or a combination of any of the foregoing.Subject

[0224] In some embodiments, a subject (e.g., a human subject) receiving the biomaterial as provided herein may have received a therapy for the disease other than the delivery articleWSGR Docket No. 56745-707.601prior to the implanting. In some cases, the subject may have received the therapy at least 1 week, at least 2 weeks, at least 4 weeks, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, or at least 12 months prior to the implantation of the delivery device. In some cases, the therapy was received after the subject was diagnosed with the disease. In some cases, the subject may have not responded to the therapy. In some cases, the subject experienced a morbidity of the disease after the therapy. In some cases, the subject experienced a morbidity of the disease 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months after the therapy. In some cases, the therapy may be unavailable for the subject after the morbidity of the disease. In some cases, the therapy may be unsuitable for the subject after the morbidity as determined by a physician. In some cases, the therapy may be surgery. In some cases, the therapy may comprise systemic administration. In some cases, the therapy may comprise chemotherapy.EMBODIMENTS

[0225] The following non-limiting embodiments provide illustrative examples of the invention, but do not limit the scope of the invention:

[0226] Embodiment 1. A method comprising: a) feeding polycaprolactone into an extruder; b) feeding 5 -fluorouracil into the extruder; c) combining and heating in the extruder the polycaprolactone and the 5 -fluorouracil to provide a combined mixture; d) extruding the heated mixture through a die to provide a monofilament; e) cooling the monofilament to provide a cooled monofilament; and f) collecting the cooled monofilament.

[0227] Embodiment 2. The method of Embodiment 1, wherein the collecting the cooled monofilament comprises removing the monofilament from the extruder by conveyor belt.

[0228] Embodiment 3. The method of Embodiment 2, wherein the conveyor belt is cooled.

[0229] Embodiment 4. The method of any one of Embodiments 1-3, wherein the collecting the cooled monofilament comprises spooling the cooled monofilament around a spool.

[0230] Embodiment 5. The method of any one of Embodiments 1-4, wherein the polycaprolactone is fed into the extruder as pellets.

[0231] Embodiment 6. The method of any one of Embodiments 1-5, wherein the 5-fluorouracil is fed into the extruder as a powder.

[0232] Embodiment 7. The method of any one of Embodiments 1-6, wherein the extruder is a single-screw hot melt extruder.WSGR Docket No. 56745-707.601

[0233] Embodiment 8. The method of any one of Embodiments 1-7, wherein the combining of the polycaprolactone and the 5-fluorouricil occurs at about 25 °C.

[0234] Embodiment 9. The method of any one of Embodiments 1-8, wherein the heating the polycaprolactone and the 5-fluorouricil is heating to about 80 °C.

[0235] Embodiment 10. The method of any one of Embodiments 1-9, wherein the die is stainless steel.

[0236] Embodiment 11. The method of any one of Embodiments 1-10, wherein the monofilament has a cross section that is approximately circular with a diameter of about 0.1 mm to about 2 mm.

[0237] Embodiment 12. The method of any one of Embodiments 1-11, wherein the monofilament has a homogenous distribution of 5-fluorouricil in polycaprolactone.

[0238] Embodiment 13. The method of any one of Embodiments 1-12, wherein the monofilament has a homogenous distribution of 5-fluorouricil in polycaprolactone, wherein the distribution is about 20% to about 40% 5 -fluorouracil by mass.

[0239] Embodiment 14. The method of any one of Embodiments 1-13, wherein the cooling of the monofilament is by blowing air on the monofilament.

[0240] Embodiment 15. A method comprising: a) providing an extruding system, wherein the extruding system comprises: 1) an extruder screw comprising: a material entry point, a material exit point, and at least one thermal zone disposed between the material entry point and the material exit point; 2) a material hopper disposed above the extruder screw, wherein the material hopper comprises a base; 3) a motor disposed at the base of the material hopper, wherein the motor mechanically regulates flow from the material hopper to the material entry point of the extruder screw; 4) a die operably connected to the material exit point of the extruder screw; 5) an air blower positioned to blow air on material that passes through the die; 6) a conveyor belt positioned to receive material that passes through the die, wherein the conveyor belt conveys material from the die to a spooler; and 7) the spooler, positioned to receive material from the conveyor belt and spool the material on a spool; b) feeding polycaprolactone into the material hopper; c) feeding 5-fluorouricil into the material hopper; d) passing, by the motor, polycaprolactone and 5-fluorouricil from the material hopper to the material entry point of the extruder screw; e) combining the polycaprolactone and 5-fluorouricil by the extruder screw and passing the polycaprolactone and 5-fluorouricil through the thermal zone to the material exit point to provide a combined mixture; f) extruding the combined mixture through the die to provide a monofilament; g) blowing air,WSGR Docket No. 56745-707.601by the air blower, on the monofilament to cool the monofilament; h) receiving by the conveyor belt the monofilament; i) conveying by the conveyor belt the monofilament to the spooler; and j) spooling by the spooler the monofilament around a spool.

[0241] Embodiment 16. The method of Embodiment 15, wherein the conveyor belt is cooled.

[0242] Embodiment 17. The method of Embodiment 15 or 16, wherein the poly caprolactone is fed into the extruder as pellets.

[0243] Embodiment 18. The method of any one of Embodiments 15-17, wherein the 5-fluorouracil is fed into the extruder as a powder.

[0244] Embodiment 19. The method of any one of Embodiments 15-18, wherein the extruder screw is a single-screw hot melt extruder.

[0245] Embodiment 20. The method of any one of Embodiments 15-19, wherein the thermal zone has a temperature of about 80 °C.

[0246] Embodiment 21. The method of any one of Embodiments 15-20, wherein the die is stainless steel.

[0247] Embodiment 22. The method of any one of Embodiments 15-21, wherein the monofilament has a cross section that is approximately circular with a diameter of about 0.1 mm to about 2 mm.

[0248] Embodiment 23. The method of any one of Embodiments 15-22, wherein the monofilament has a homogenous distribution of 5-fluorouricil in polycaprolactone.

[0249] Embodiment 24. The method of any one of Embodiments 15-23, wherein the monofilament has a homogenous distribution of 5-fluorouricil in polycaprolactone, wherein the distribution is about 20% to about 40% 5 -fluorouracil by mass.

[0250] Embodiment 25. A method comprising: a) extruding a monofilament through a nozzle onto a print bed to print an article, wherein the article is printed in a shape characterized by any drawing or description provided herein; b) cooling the print bed to about room temperature; and c) removing the article from the print bed.

[0251] Embodiment 26. The method of Embodiment 25, wherein the print bed is borosilicate glass.

[0252] Embodiment 27. The method of Embodiment 25 or 26, wherein the extruding comprises drawing the monofilament into an extruder assembly by a stepper motor and extruding the monofilament through the nozzle.

[0253] Embodiment 28. The method of any one of Embodiments 25-27, wherein the removing the printed device from the print bed is done manually.WSGR Docket No. 56745-707.601

[0254] Embodiment 29. The method of any one of Embodiments 25-28, further comprising disposing a spool of the monofilament on a roller and feeding the monofilament into an extruding assembly for the extruding.

[0255] Embodiment 30. The method of any one of Embodiments 25-29, wherein the monofilament has a homogenous distribution of 5-fluorouricil in polycaprolactone.

[0256] Embodiment 31. The method of any one of Embodiments 25-30, wherein the monofilament has a homogenous distribution of 5-fluorouricil in polycaprolactone, wherein the distribution is about 20% to about 40% 5 -fluorouracil by mass.

[0257] Embodiment 32. The method of any one of Embodiments 25-31, further comprising placing the article in pharmaceutically-acceptable packaging.

[0258] Embodiment 33. The method of Embodiment 32, wherein the pharmaceutically-acceptable packaging is a clamshell blister.

[0259] Embodiment 34. The method of Embodiment 32 or 33, further comprising labeling the pharmaceutically-acceptable packaging.

[0260] Embodiment 35. The method of any one of Embodiments 32-34, further comprising placing the pharmaceutically-acceptable packaging in an aluminum pouch.

[0261] Embodiment 36. The method of Embodiment 35, further comprising placing a bag of silica in the aluminum pouch.

[0262] Embodiment 37. The method of Embodiment 35 or 36, further comprising purging the aluminum pouch with nitrogen gas.

[0263] Embodiment 38. The method of any one of Embodiments 35-37, further comprising sealing the aluminum pouch.

[0264] Embodiment 39. The method of any one of Embodiments 35-38, further comprising labeling the aluminum pouch.

[0265] Embodiment 40. The method of any one of Embodiments 35-39, further comprising packing the aluminum pouch in a carton.

[0266] Embodiment 41. The method of Embodiment 40, further comprising packing the carton in a transporter box.

[0267] Embodiment 42. The method of Embodiment 41, further comprising shipping the transporter box to a destination.

[0268] Embodiment 43. The method of any one of Embodiments 32-42, further comprising irradiating the article with gamma radiation to promote sterilization.

[0269] Embodiment 44. A method of treating or preventing a disease or condition, comprising:WSGR Docket No. 56745-707.601implanting into a subject one or more delivery articles, wherein a delivery article of the one or more delivery articles comprises a plurality of geometric elements, wherein the delivery article comprises a polymer and an active agent, wherein, when administered to a subject, the one or more delivery articles deliver the active agent to a target tissue or region.

[0270] Embodiment 45. The method of Embodiment 44, wherein an amount of the active agent delivered to the target tissue or region is measured by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS / MS) or High-Performance Liquid Chromatography (HPLC).

[0271] Embodiment 46. A method of preferentially delivering an active agent to a target tissue or region of a subject to treat or prevent a disease or condition, comprising:implanting into the subject one or more delivery articles, wherein a delivery article of the one or more delivery articles comprises a plurality of geometric elements, wherein the delivery article comprises a polymer and an active agent, wherein a concentration of the active agent is higher in the target tissue or region than a non-targeted tissue or region.

[0272] Embodiment 47. The method of Embodiment 46, wherein the concentration of the active agent is measured by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS / MS) or High-Performance Liquid Chromatography (HPLC).

[0273] Embodiment 48. The method of Embodiment 46 or 47, wherein the concentration of the active agent is at least 2-fold, at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, at least 100-fold, at least 200-fold, or at least 500-fold higher in the target tissue or region than in the non-target tissue or region.

[0274] Embodiment 49. The method of any one of Embodiments 46-48, wherein the nontarget tissue or region is liver or blood vessel.

[0275] Embodiment 50. The method of any one of Embodiments 44-49, wherein the target tissue comprises colorectal site, peritoneal site, or mesentery site.

[0276] Embodiment 51. The method of Embodiment 50, wherein the target tissue comprises the colorectal site, optionally wherein the colorectal site comprises intraluminal site or serosa of bowel.

[0277] Embodiment 52. The method of Embodiment 50, wherein the target tissue comprises the peritoneal site, optionally wherein the peritoneal site comprises peritoneal wall, left peritoneal cavity, or right peritoneal cavity.

[0278] Embodiment 53. The method of Embodiment 50, wherein the target tissue comprises the mesentery site.

[0279] Embodiment 54. The method of any one of Embodiments 44-53, wherein the disease or condition is cancer or tumor.WSGR Docket No. 56745-707.601

[0280] Embodiment 55. The method of any one of Embodiments 44-54, wherein the implanting comprises implanting the one or more delivery articles into or adjacent to the target tissue of the subject.

[0281] Embodiment 56. The method of any one of Embodiments 44-55, wherein the implanting comprises implanting at least a first delivery article and a second delivery article into the subject.

[0282] Embodiment 57. The method of Embodiment 56, wherein the first delivery article is coupled to the second delivery article.

[0283] Embodiment 58. The method of Embodiment 56 or 57, wherein the first delivery article comprises a first plurality of geometric elements and the second delivery article comprises a second plurality of geometric elements.

[0284] Embodiment 59. The method of Embodiment 58, wherein a first shape of the first plurality of geometric elements is coupled to a second shape of a second plurality of geometric elements.

[0285] Embodiment 60. The method of any one of Embodiments 44-59, wherein the active agent is released locally at or near the site of implantation as determined by tissue bioanalysis.

[0286] Embodiment 61. The method of any one of Embodiments 44-60, wherein the active agent is substantially not released to the systemic circulation as determined by plasma bioanalysis.

[0287] Embodiment 62. The method of any one of Embodiments 44-61, wherein the active agent is released locally with a level of 100 to 5000 nanograms per gram (ng / g), compared to a level in the blood vessel or plasma therein below 15 nanograms per milliliters (ng / mL).

[0288] Embodiment 63. The method of any one of Embodiments 44-62, wherein the subject received a therapy for the disease or the condition other than the drug delivery article prior to the implanting.

[0289] Embodiment 64. The method of any one of Embodiments 44-63, wherein the therapy was received after the subject was diagnosed with the disease or the condition.

[0290] Embodiment 65. The method of any one of Embodiments 44-64, wherein the subject has not responded to the therapy.

[0291] Embodiment 66. The method of any one of Embodiments 44-65, wherein the subject experienced a morbidity of the disease or the condition after the therapy.

[0292] Embodiment 67. The method of any one of Embodiments 63-66, wherein the therapy is surgery.WSGR Docket No. 56745-707.601

[0293] Embodiment 68. The method of any one of Embodiments 63-66, wherein the therapy comprises systemic administration.

[0294] Embodiment 69. The method of any one of Embodiments 63-66, wherein the therapy comprises chemotherapy.

[0295] Embodiment 70. The method of any one of Embodiments 44-69, wherein the disease comprises a cancer.

[0296] Embodiment 7E The method of any one of Embodiments 44-70, wherein the one or more delivery articles is implanted adjacent to a tumor.

[0297] Embodiment 72. The method of any one of Embodiments 44-71, wherein the one or more delivery articles is implanted at most 1 centimeter (cm) away from the tumor.

[0298] Embodiment 73. The method of any one of Embodiments 44-72, wherein the drug delivery article is implanted over a tumor.

[0299] Embodiment 74. The method of Embodiment 73, wherein at least a portion of the drug delivery article covers at least a portion of the tumor.

[0300] Embodiment 75. The method of any one of Embodiments 71-74, wherein the tumor comprises a solid tumor.

[0301] Embodiment 76. The method of any one of Embodiments 71-74, wherein the tumor comprises a colorectal tumor.

[0302] Embodiment 77. The method of Embodiment 76, wherein the subject has been subjected to a total neoadjuvant therapy (TNT).

[0303] Embodiment 78. The method of any one of Embodiments 71-74, wherein the tumor comprises a rectal tumor.

[0304] Embodiment 79. The method of any one of Embodiments 71-74, wherein the tumor comprises an anal tumor.

[0305] Embodiment 80. The method of any one of Embodiments 71-74, wherein the tumor comprises a lower gastrointestinal tract tumor.

[0306] Embodiment 81. The method of any one of Embodiments 71-74, wherein the tumor comprises a pancreatic tumor.

[0307] Embodiment 82. The method of any one of Embodiments 71-74, wherein the tumor comprises a lung tumor.

[0308] Embodiment 83. The method of any one of Embodiments 71-74, wherein the tumor comprises a bone tumor.

[0309] Embodiment 84. The method of any one of Embodiments 44-83, wherein the implanting comprises suturing the drug delivery article to a tissue of the subject.WSGR Docket No. 56745-707.601

[0310] Embodiment 85. The method of any one of Embodiments 44-84, wherein the implanting comprises an endoscopic procedure.

[0311] Embodiment 86. The method of any one of Embodiments 44-85, wherein the active agent comprises a therapeutic agent.

[0312] Embodiment 87. The method of any one of Embodiments 44-86, wherein the active agent is substantially uniformly dispersed in a portion of the delivery article.

[0313] Embodiment 88. The method of any one of Embodiments 44-87, wherein a geometric element of the plurality of geometric elements is formed by a porous border.

[0314] Embodiment 89. The method of any one of Embodiments 44-88, wherein a geometric element of the plurality of geometric elements is formed by a non-porous border.

[0315] Embodiment 90. The method of any one of Embodiments 44-89, wherein a shape of a geometric element of the plurality of geometric elements is triangle, rectangle, square, diamond, pentagon, hexagon, polygon, circle, or oval.

[0316] Embodiment 91. A kit comprising: a container comprising the one or more delivery articles of any one of Embodiments 44-90; and instructions for use.

[0317] Embodiment 92. The kit of Embodiment 91, further comprising another container comprising one or more tools configured to implant a delivery article to a subject.EXAMPLES

[0318] The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.EXAMPLE 1: Preparation of drug delivery article

[0319] This example illustrates a method for preparing a drug delivery article. The method comprises a hot-melt extrusion process to generate monofilament and a three-dimensional printing (3 DP) process to produce the drug delivery article.

[0320] Hot-melt extrusion: polycaprolactone (PCL) pellets and 5 -fluorouracil (5-FU) powder were gravimetrically fed from a material hopper into a single-screw hot melt extruder (EIME). A small motor was used at the base of the material hopper to advance material out of the hopper. After entering the extruder screw, homogenization of PCL and 5-FU occurred in a closed -system environment. The room temperature (~25 °C) mixture was then advanced through the thermal zones in the HME to gradually increase the temperature to PCL glass transition temperature (~80 °C). The top of the material hopper was open to the room, as well as a small portion of the HME system where the material from the hopper entered the screw mechanism.WSGR Docket No. 56745-707.601

[0321] Extrusion of the heated mixture was performed through a stainless-steel die to produce a monofilament with circular profile and the desired cross-sectional diameter. When HME was performed properly, this monofilament had a homogenous distribution of 5-FU embedded within the PCL (between 20 wt% and 40 wt%). The extruded monofilament was cooled via actively blowing filtered air, advanced away from the extruder, and towards the spooler on a conveyor belt, which was also actively cooled. As the monofilament came off the conveyor belt, it was placed around a spool, which wound the monofilament into the final spooled material to be used for 3D printing.

[0322] 3D Printing (3DP)-. The spooled monofilament was placed on rollers on the top surface of the 3D printer. The monofilament was advanced through a small opening at the top of the 3D printer and into a PTFE tube that led into the 3D printer’s extruder assembly. To ensure proper material flow and feed into the system, a small amount of material (<5 g) was extruded from the 3D printer’s extruder assembly. When the printing process commenced, the monofilament was drawn into the 3D printer’s extruder assembly by a stepper motor and extruded through a stainless steel nozzle onto the print bed or build plate (borosilicate glass), where the monofilament rapidly cooled from its glass transition temperature (-80-100 °C) to an intermediate temperature (-50 °C), providing good adhesion to the print bed without impacting the structure of the printed drug delivery article. The 3D printer’s extruder assembly was in an enclosed environment and any particulates generated through the grabbing and pulling action of the stepper motor were contained entirely within the extruder assembly. Once the printing process was complete, the borosilicate glass build plate was allowed to cool to room temperature, at which point the printed drug delivery article was removed with tweezers or forceps, and then placed in a pouch for sterilization.EXAMPLE 2: Manufacturing of drug delivery article

[0323] This example illustrates a method for manufacturing drug delivery articles disclosed herein. The drug delivery article comprising 5 -fluorouracil (5-FU or 5FU) as an active agent was prepared. Poly caprolactone (PCL) was used as an excipient. The PCL has a molecular weight of 37,000 (PCL37k) or 50,000 (PCL50k). The manufacturing process was performed in a clean-room environment with open product handling. The facilities were continuously monitored, and clean rooms are designed according to EU Grade D. For a process run of approximately 100 chips, the batch formula for the 3 intermediate materials used is shown in Table 2. FIG. 11 shows an example workflow of the preparation process.Table 2. Batch formulaWSGR Docket No. 56745-707.601Chip Type 100 chip batch (g) 5FU (g) PCL37k (g) PCL50k (g) 0.8 mm polymer- 21 2.1 2.6 16.35FU (20 mg)

[0324] Mixing of 5-FU with polymer', three drug delivery articles were generated: 1) PCL37k + 5FU (or referred to as “API”); 2) PCL50k + 5FU; and 3) PCL50k (alone). PCL (37 kDa or 50 kDa) and 5-FU were mixed at a ratio of 20% drug weight in two gravimetric feeders.

[0325] Extrusion and Intermediate Storage ', a hot melt extruder was used to extrude the PCL-5FU (or PCL alone) into strands of approx. 2 mm diameter that were then wound onto cleaned transparent PET spools, using a filament spooler with hygienic contact surfaces with FDA approved materials. Spools were placed in sealed PE or aluminum pouches until further use.

[0326] Quality control IOC) samples of the extruded material were visually inspected; analytical parameters to be tested for each batch (experimental and clinical) included (i) amount of 5FU in mix (wt%); and (ii) GPC (Mn, Mw, Mn / Mw).

[0327] Biomaterial printing', desired amount / range of extruded material was weighed. Each set of PCL and PCL-API composite were placed into one of the three printer extrusion chambers. Drug delivery article was produced via an extrusion-based additive manufacturing (AM) process wherein the three constituent ratios of PCL and API were precisely deposited in specific, three-dimensional spatial locations. Deposition was done by placing each set of PCL and PCL-API composite into one of the three extrusion chambers and heating the chambers until the PCL reaches its glass transition temperature and was able to flow (approximately 100 °C). Once the glass transition temperature was achieved, a pneumatic system pushed the PCL and / or PCL-API composite through a stainless steel syringe tip and precisely deposit the material in pre-specified locations, building up the entire biomaterial construct layer-by-layer. By extruding material precisely at the glass transition temperature, the extruded material transitioned back to a fully solid state as soon as extruded out of the system (e.g., substantially upon extrusion from the system). This process provides very little geometric or structural variation from chip to chip. The successful fabrication of biomaterial through AM was achieved through a specific, validated, and pre-determined machine code that determined the motions, flow rates, and temperatures achieved by the 3D printer over the entire duration of the printing process (approximately 10 minutes). The mechatronic systems controlling the 3D printer have numerous feedback loops, safety checks, and sensor systems, which keep the system within a tight operating envelope with respect to material temperature,WSGR Docket No. 56745-707.601composition, spatial resolution, and mass flow rate. As such, the proper operation of these systems can be crucial to the successful manufacture of the biomaterial and regular calibration checks can be performed using independent validation systems (in addition to the control systems built-in to the 3D printer) to ensure the system is consistently operating within the accepted range of values. In some embodiments, a method of making disclosed herein comprises use of a process in which three chambers are used to print the discrete regions of biodegradable polymer or polymer-drug mixtures that characterize the biomaterial design and provide the desired biodegradation behaviors and drug release profiles. For example, three chambers (each containing PCL37k-5FU, PCL50k-5FU, or PCL50k alone) are heated to 105 °C, the point at which the polymer or polymer-drug mixtures can flow, and pneumatic pressure is applied to drive the material out of a nozzle affixed to the stainless steel chamber. The three distinct chambers allow for the geometrically desired printing of 3 distinct materials each of which can thus be very precisely controlled in its spatial deposition.

[0328] Quality control (QC) : visual inspection, biomaterial dimension (length, width, and thickness) and mass were measured. These measurements can indicate whether the total amount of 5FU in the chip is within specification. The amount of 5FU per chip was measured. 5FU and polymer quality were monitored.

[0329] Primary Packaging', the biomaterial (or chip) was placed in a clamshell blister. The blister was labelled. The blister was placed in an aluminium pouch with optionally a silica bag and optionally purged with nitrogen before sealing. The pouch was labelled. The seal was 100% visually inspected by two operators for seal quality (e.g., detecting presence of creases). If the seal was considered faulty, the biomaterials were removed from the pouch and the blister with product was placed in a fresh labelled pouch and further processed as described herein.

[0330] Secondary Packaging', ten chips were packaged in a carton box (approximate dimensions- e.g., 2”x2”x3”) and boxes were packaged in a transporter (e.g., reusable, cool, cardboard). For example, ten chip units were packaged in a carton box (approximate dimensions- e.g., 7”x4”x6”) and not more than 50 carton boxes were packaged in a carton transporter. The transporter was a defined, fixed size box used during sterilization. Lesser quantities of 10-chip cartons can be transported to individual clinical sites. Transportation of the material can be done at a maximum temperature of 75 degrees Fahrenheit. FIG. 12 provides a packaging process for chips.WSGR Docket No. 56745-707.601

[0331] Sterilization', following provisional release, boxes with chips in primary packaging were sent to the sterilizer for gamma irradiation. The transporter boxes can be individually gamma irradiated.

[0332] QC. transporter boxes can be opened and a subset of packages of chips were evaluated for bioburden, endotoxin, and sterility. Upon return of the products, a visual inspection of the gamma dot can be done as well as the inspection of the sterilization certificate and dosage report (FIG. 13). The biomaterial can be supplied as a sterile, solid / flexible surgical article packaged in a clamshell blister, sealed within an aluminum pouch (or, e.g., silica bag), optionally purged with nitrogen before sealing, and labeled. A label can comprise, for example, a serial or batch number, a dosage, a percent of an active drug (e.g., w / w, w / v, or v / v), and instructions for storage of the drug (e.g., 15 -25 °C, do not freeze).EXAMPLE 3: Overview of dosage form, manufacturing, and administration

[0333] Dosage form’. polymer-5FU is a flexible extended-release biodegradable dosage form composed of fluorouracil encapsulated in a pure polymer matrix (polycaprolactone, PCL). Each polymer-5FU (20 mg) contains 20 mg of 5 -fluorouracil. A 2-dimensional image of the chip design is shown in FIG. 9A and a photograph is shown in FIG. 9B. Approximate dimensions of polymer-5FU were 20 mm x 20 mm x 0.8 mm (LxWxH). Mass was approximately 200 mg.

[0334] Brief Overview of Manufacturing Process', chips were produced using an Additive Manufacturing (AM) multi-extruder printing system that uses three containers with either biodegradable polymer or polymer-drug mixtures. The printer deposits the materials listed in Table 3 in a very precisely controlled spatial organization to form a structure which contains 4 drug compartments. For the polymer-5FU, two compartments contain PCL37k with active pharmaceutical ingredient (API; see FIG. 9A, darkest shading) and two contain PCL50k with API (see FIG. 9 A, central parts with medium shading shading), and 50k PCL supporting material alone (see FIG. 9A, light shading).Table 3. Distribution of 5-FU in regions of polymer-5FU chip Section - Compartment- Segment Amount per unit (Chip)5FU PCL Polycaprolactone + 5 -fluorouracil (MW: 37,000) 8 mg 32 mg Polycaprolactone + 5 -fluorouracil (MW: 50,000) 12 mg 40 mgWSGR Docket No. 56745-707.601Polycaprolactone alone (MW: 50,000) 0 40 mgTotal 20 mg

[0335] Route of Administration', the chip is implanted / placed adjacent to tumors. More than one chip can be implanted by connecting one chip to another through suturing the corner hexagonal structures together. The chip can be administered by a method that utilizes endoscopy, colonoscopy, or traditional open surgery.

[0336] FIG. 10 shows schematics of an example biomaterial (chip) that is inserted (Insertion), after 24 h of implantation (24 Hours), after 30 days of implantation (30 Days), and after removal from the subject (Removal). Dots illustrate the released drug from the biomaterial to the subject. Arrows show the direction of the drug release. In some embodiments, the biomaterial is at least partially degraded after implantation in the subject.Example 4: Preclinical studies

[0337] The initial safety profile of polymer-5FU chip was established in a healthy rat model (Study A). The objective of the study was to determine gross and local toxicity of Biomaterial when implanted subcutaneously. No major toxicology or safety concerns were seen. No gross toxicity seen in the five major organs. Mild local inflammatory response in line with foreign body implants at the site was seen in all 3 animals.

[0338] Efficacy was tested in murine model (Study B). CT26 colorectal cell lines in a murine model were chosen to conduct toxicity and safety studies in-vivo. The safety profile of polymer-5FU chip was compared with other control groups, and five aspects were evaluated as follows: (i) change in the body weight over time, (ii) organ weight and the ratio of organ to body weight, (iii) Hematoxylin-Eosin (H&E) staining for histological changes, (iv) a hepatic function panel, and (v) blood chemistry to assess impact on bone marrow. For H&E staining, five major organs (liver, heart, spleen, lungs, and kidneys) were collected from the mice at each time point. The chip did not have any effects on vital organ functions, including cardiovascular, respiratory and central nervous system. All organs exhibited no signs of local or systemic toxicity with the application of the chip. The chip demonstrated a superior safety profile (p <0.05) in comparison to intravenous bolus of 5-FU in short-term toxicity as shown by blood chemistry. The study showed no significant toxic effects, enzyme levels of all treatment groups were not statistically different from the untreated control group. Short-term whole blood toxicity, 3 days post-treatment, displayed differences in the blood counts between the groups (IntraVenous vs chip). Data showed that IV 5-FU by itself had a toxicWSGR Docket No. 56745-707.601effect, as indicated by the reduction in the absolute numbers of white blood cells. This toxic effect was not observed in mice treated with the chip. Subpopulations of white blood cells exhibited signs of potential toxicity for animals treated with systemic (intravenous) 5-FU: a reduction in the number of monocytes and other leukocytes, indicating bone marrow suppression. This toxic effect was not observed in mice treated with Biomaterial-5-FU.

[0339] Treatment with chip in CT26 colorectal mice demonstrated a delay in tumor growth and statistically significant reduction of tumor burden. A pre-clinical non-GLP efficacy study showed sustained release of local 5-FU onto the subcutaneous CT26 colorectal carcinoma murine model as well. In comparison to a blank chip or no intervention, the mice treated with the chip exhibited the smallest tumor weight increases, significantly smaller tumor burden than the untreated and blank chip (P<0.05). Mice in the groups receiving 5-FU (the chip and 5-FU unconfigured chip) exhibited slower tumor growth compared to the mice in groups that did not receive 5-FU (untreated group and blank PCL group). This was evidenced by smaller increases in the tumor weight. By day 19 the chip demonstrated a strong anti -turn or effect compared to other interventions.

[0340] Dose escalation toxicities were tested in large porcine model (Study C) with up to 5 chip units placed within the peritoneal cavity. In a 3-day study, the safety profile of the chip was determined by (i) change in the body weight over time, (ii) change in bowel movements or displacement of Biomaterial, (iii) gross pathological changes, (iv) Hematoxylin-Eosin (H&E) staining for histological changes, and (v) blood chemistry at the following timepoints; pre-dose, 8 hours, 16 hours, 24 hours, 32 hours, 40 hours, 48 hours, and 72 hours. For H&E staining, five major organs (liver, heart, spleen, lungs, and kidneys) were collected from the pig at the end of study. No organs exhibited signs of local or systemic toxicity with the application of the chip. No changes in body weight over time were seen. No change in bowel movements were observed. No displacement of the chip surgically applied into the intraluminal aspect of the bowel occurred. No blood chemistry tests exhibited signs of systemic toxicity or dose-associated systemic toxicity. No abnormalities were seen on gross inspection of the five major organs (liver, heart, spleen, lungs, and kidneys). No systemic adverse effects, nor significant local toxicity, were seen in the highest dose (5 chip units). No meaningful toxicological, neurological or histological findings were observed in the in-vivo studies except for localized inflammation (< 1mm) at the site of implantation on visual inspection at the time of necropsy.

[0341] These studies established preclinical proof of principle. Collectively these preclinical studies support the concept that the chip is a safe and efficient local delivery system, withWSGR Docket No. 56745-707.601minimal dose-limiting systemic adverse effects. Table 4 summarizes the pre-clinical study result.Table 4. Summary of pre-clinical studyStudy Species & n Overall Objective Primary OutcomeNumberStudy A Healthy Rat - Overall Safety with No major safety concerns, no gross Subcutaneous Gross and Local toxicity seen in the five major organs.n=4 Toxicity Local inflammatory response in line with foreign body implants at the site. Study B CT26 colorectal Investigate Gross & No gross or local toxicities seen, no carcinoma Local Toxicity, systemic toxicities seen. Observed murine model Systemic Toxicity in superior safety profile compared to IV n=37 comparison to IV 5-FU 5-FU.Study C Healthy pigs - Investigate Gross and Localized inflammatory response Direct Organ Local Toxicity observed at the site of implant upon Contact - Dose tissue collection. No gross toxicities in Escalation five organs. Local histopathology n=3 pending.

[0342] Nonclinical Pharmacology / Non Clinical Pharmacokinetics:

[0343] In Study C, the pharmacokinetics of chip with 5-FU were evaluated through tissue and blood analysis. At the following timepoints, blood samples to determine the concentration of systemic 5-FU were taken: pre-dose, 8 hours, 16 hours, 24 hours, 32 hours, 40 hours 48 hours and 72 hours. Given the local nature of the product and quantity of 5-FU, systemic exposure of 5-FU was not expected to be above the level of detection. The majority of the 5-FU concentration was found locally, around the chip.

[0344] Pig 1 received 1 chip (colorectal-intraluminal bowel), Pig 2 received 3 chips (Colorectal - serosa of bowel, Peritoneal Wall, and Peritoneal Wall near Liver), and Pig 3 received 5 chips (colorectal - serosa of bowl, colorectal - serosa of bowel within 2 cm of the above placement, Left Peritoneal cavity, Right Peritoneal cavity, and Mesentery).

[0345] Toxicology and Histology:

[0346] The Chip has been shown to exhibit systemic safety in porcine in vivo model systems. Chip delivered 5-FU directly to the desired tissue site without systemic adverse effects.

[0347] Histology: healthy porcine model:

[0348] High power image of specimen submitted as colon-MediChip contact. FIG. 16 shows the photomicrographs. Box 1 highlights the mucosal architectural changes observed at one ofWSGR Docket No. 56745-707.601the fragments, consisting of focal loss epithelial lining and cellular debris in the underlying submucosal layer, with focal hemorrhage, and fibrinoid necrosis of single arteriole (box 2). Focal necrosis of the muscularis propria and serosa is shown in box 3 with suppurative inflammation, reparative changes with reactive fibroblasts present at the serosal aspect, and fibrin deposition on its surface. (Stained with H&E).Example 5: Preclinical study

[0349] The present disclosure provides a polymer-based drug delivery system that allows the pharmacological agent to be directly placed at the tumor site and retains the agent at the site of action, thereby limiting its release into systemic circulation.

[0350] Polymer-5FU chip containing milligram quantities of 5 -fluorouracil were surgically implanted onto the colon, mesentery and peritoneal tissues of three Yucatan pigs. Pig 1 received 1 chip (Colon), Pig 2 received 3 chips (Colon, Peritoneal Wall, and Peritoneal Wall near Liver), and Pig 3 received 5 chips (Caudal Colon, Cranial Colon, Left Peritoneal Wall, Right Peritoneal Wall, and Mesentery). Plasma samples were drawn at 0 hr, 8 hr, 16 hr, 24 hr, 32 hr, 40 hr, 48 hr and 72 hr post-implantation. Following the last plasma collection, the animals were euthanized, and tissues were harvested for analysis. Tissues collected include sites of implantation and untreated liver samples. The animals maintained good clinical health, with no adverse events. Hematological and biochemical parameters remained within expected physiological ranges.

[0351] Porcine plasma and tissues were received on dry ice and promptly stored at -80 °C until analysis. 5-FU reference standard (> 99% pure) was stored at -20 °C as a powder sample. 1 mg powder sample of the internal standard,13C,15N-5-FU was dissolved in water containing 0.1% formic acid to a concentration of 1 mg / ml and stored at -20 °C. A reference stock solution (RSS) of 5-FU was prepared at 1 mg / mL in 0.1% formic acid in water. A reference stock solution (RSS-IS) of13C,15N-5-FU was prepared at 1 mg / mL in 0.1% formic acid in water. A working stock solution (WSS) of 5-FU was prepared by diluting the RSS to a final concentration of 80 pg / mL by transferring 80 pL of RSS to a 1.5 mL Eppendorf tube and diluting to 1 mL with 0.1% formic acid in water. Sub-working stock solutions of 5-FU were made by serial dilution into water containing 0.1% formic acid. A total of 12 subworking stock solutions (80, 40, 20, 8, 4, 2, 0.8, 0.4, 0.2, 0.08, 0.04, and 0 pg / mL) were prepared. 11 plasma calibration standards of 5-FU and 1 plasma blank were prepared. To prepare the top calibration standard (Standard 11), 2.5 pL of the 80 pg / mL WSS was diluted into 47.5 pL of blank plasma to a concentration of 4000 ng / mL. Subsequently, the remainingWSGR Docket No. 56745-707.601ten 5-FU plasma calibration standards were prepared in a similar manner (0, 2, 4, 10, 20, 40, 100, 200, 400, 1000, 2000, 4000 ng / mL). Extraction solvent was prepared containing internal standard at a concentration of 200 ng / mL and was prepared by taking a 10 pL aliquot of the RSS-IS and diluting to 50 mL with acetonitrile. Calibration standards, blanks and plasma study samples (plasma) were processed for LC / MS / MS (Liquid Chromatography-Tandem Mass Spectrometry) analysis by precipitating 50 pL of each plasma calibrator and each plasma study sample with 3x volume (150 pL) of extraction solvent. Addition of extraction solvent resulted in precipitation of plasma proteins. Samples were vortexed for 1 minute and then transferred to a 5417REppendorf centrifuge and centrifuged at 14000g for 6 minutes. Following centrifugation, 150 pL of each supernatant was transferred to a shallow well, v-bottom microtiter plate. The plate was sealed and analyzed by LC-MS-MS. Colon, mesentery, peritoneal and liver tissues were harvested from the same Yucatan pigs and received in 50 mL Eppendorf tubes with tissue weights recorded. Tissues were thawed and to each was added PBS buffer in a ratio of 10 pL PBS per mg tissue. For example, for a tissue weighing 1 g, a total of 10 mL PBS was added. Tissues were homogenized using a handheld homogenizer. In between each tissue sample homogenization, the handheld homogenizer was washed thoroughly to avoid cross-contamination of tissues. Next, two separate 100 pL aliquots of each tissue homogenate were transferred to individual 1.5 mL Eppendorf tubes. To each tube was added 3x volume extraction solvent (150 pL acetonitrile containing internal standard). Samples were vortexed for 1 minute and then transferred to a 5417R Eppendorf centrifuge and centrifuged at 14000g for 6 minutes. Following centrifugation, 150 pL of each supernatant was transferred to a shallow well, v-bottom microtiter plate. The plate was sealed and analyzed by LC-MS-MS. Mobile phase 50 mM was ammonium formate in water, pH adjusted to 8 with NH4OH. Mobile phase B was acetonitrile. Injection volume was 1 pL.

[0352] Tissue samples received were grossly examined for abnormalities and digitally photographed. Measurements were taken and each fragment was inked accordingly. The tissues fixed with 10% buffered formalin were transferred to an appropriate barcode-labeled biopsy cassette and submitted for paraffin processing. The entire specimen was submitted for light microscopy. Tissues were dehydrated in a graded series of ethanol and xylene and embedded in paraffin. Each paraffin block was serially cut at 4-6 pm by a rotary microtome and placed on labeled glass slides. The slides from each sample were stained with hematoxylin and eosin (HE). All slides were evaluated for histopathologic abnormalities. All histology slides were examined using light microscopy. The tissue samples were graded using a narrative description of findings, including presence of inflammation, necrosis and / orWSGR Docket No. 56745-707.601other pertinent findings. Histologic images of all sections per animal were obtained using an Olympus BX41 brightfield microscope equipped with a trinocular port and an Olympus DP 71 Trinocular Camera. OlympusCellCens software was used to interface with the camera. Lengths relative to individual objects were established, based on a micrometer which was maintained to NIST traceable standards through Klarmann Rulings.

[0353] Plasma bioanalysis showed either no or low ng / mL levels of 5 -fluorouracil (less than 15 ng / mL). Further, there was no evidence of 5 -fluorouracil plasma accumulation over time. The plasma calibrator concentration range for the quantitation of 5-FU in plasma was 2 ng / mL to 4000 ng / mL. Pre-treatment plasma (i.e., pre-dose) showed no detectable level of 5-FU. The amount of measured 5-FU was either undetected or below 15 ng / mL in all animals across all time-points, as shown in FIG. 14A. FIG. 14A provides a pictorial representation of the differences in plasma exposure observed for the 3 treated animals. In all samples, the measured exposure was well below the reported exposure of 5-FU in plasma following conventional treatment, which ranges from 79 ng / mL to 1791 ng / mL (Cancer Chemother Pharmacol. 2016 May 23 ;78(3): 447-464).

[0354] Although inter-animal variability was observed (in part due to the site of tissue collection), the observed exposure in treated tissues was significantly higher than that measured in plasma, as shown in FIGS. 14B-14F. FIG. 14B shows the 5-FU content in peritoneal wall. FIG. 14C shows the 5-FU content in mesentery. FIG. 14D shows the 5-FU content in liver. FIG. 14E shows the 5-FU content in colon. FIG. 14F shows a summary of the 5-FU content in different tissues. As shown in FIG. 14F, the greatest release of 5-FU was observed within the colon, with the highest release overall occurring in the cranial colonic tissue of Pig 3. Liver exposure was only observed in Pig 2, in which the chip was attached to the peritoneal wall in close contact with the liver. The lack of exposure observed in Pig 1 and Pig 3 liver samples indicate that there was no leakage of 5-FU into untreated tissues, which is consistent with the finding of very low plasma exposure in those same treated animals.

[0355] FIGS. 15A-15D show issue and histology of the animal treated with the biomaterial (the implanted chip loaded with 5-FU). FIG. 15A shows an image of the tissue sample. FIG.15B shows the locations the chip was placed and was considered the colon-implant contact area. FIG. 15C shows the preserved epithelial barrier. FIG. 15D shows the suppurative inflammation and fibrin. The colon tissue in contact with the chip shows evidence of acute and chronic injury, including areas of suppurative inflammation, fibrin deposition, foreign material (likely suture) surrounded by inflammatory cells, and reparative granulation tissue. This was healthy tissue and therefore aligned with the localized therapy thesis. While most ofWSGR Docket No. 56745-707.601the colonic epithelium remained intact, some local mucosal damage was present, including crypt loss and hemorrhage. This was expected as the chip was embedded with 5-FU (a chemotherapy agent). The submucosa exhibited mild edema, hemorrhage, thrombosed vessels, and early thrombus organization. Significant necrosis and inflammation were seen in the deeper muscle layers and at the suture line, indicating tissue response to the chip contact and foreign material. The therapeutic or device remained locally (as evidenced by tissue-level effects near the site of contact). Expected biological responses occurred at the target site, including inflammation, foreign body reaction, and reparative processes. Systemic or widespread tissue disruption was not observed, suggesting localization. The chip was a bioabsorbable implant or suture-like device, some localized inflammation and reparative tissue response were expected. Histopathological analysis confirms that the chip induced a localized and controlled tissue response at the site of application, characteristic of effective site-specific delivery platforms. The presence of focal inflammation, reparative granulation tissue, and reactive fibroblasts indicates active biological interaction limited to the immediate area of the chip contact, providing targeted delivery.

[0356] The colonic epithelium remained largely preserved, and inflammatory responses were confined without evidence of widespread tissue damage, confirming that the chip did not cause systemic or off-target effects. The observed controlled necrosis and foreign body reaction at the suture line were consistent with typical localized wound healing responses to implanted materials, further validating the safety and efficacy of the chip for localized therapeutic delivery.

[0357] No 5 -fluorouracil was detected within the untreated liver samples (pigs 1 and 3). 5-fluorouracil levels ranged from 90 ng / g to 125 ng / g in the liver of Pig 2, in which a chip had been surgically implanted onto the peritoneal tissue directly outside of the liver. Treated tissue samples displayed 5 -fluorouracil exposure ranging from 90 ng / g to 5000 ng / g, with the highest levels found within the colon. The results of this study confirm that drug exposure is observed and localized at or near the site of tissue implantation without significant release into systemic circulation. These findings demonstrate that the chip disclosed herein provides targeted exposure of anti-cancer drugs to the cancerous tissue whilst reducing exposure to non-cancerous tissues.

[0358] While preferred embodiments of the present disclosure have been shown and described herein, such embodiments are provided by way of example only. It is not intended that the present disclosure be limited by the specific examples provided within the specification. While the present disclosure has been described with reference to theWSGR Docket No. 56745-707.601aforementioned specification, the descriptions and illustrations of the embodiments herein are not meant to be construed in a limiting sense. Numerous variations, changes, and substitutions will now occur without departing from the present disclosure. Furthermore, it shall be understood that all aspects of the present disclosure are not limited to the specific depictions, configurations or relative proportions set forth herein which depend upon a variety of conditions and variables. It should be understood that various alternatives to the embodiments of the present disclosure described herein can be employed in practicing the present disclosure. It is therefore contemplated that the present disclosure shall also cover any such alternatives, modifications, variations or equivalents. It is intended that the following claims define the scope of the present disclosure and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Claims

WSGR Docket No. 56745-707.601CLAIMS WHAT IS CLAIMED IS:

1. A method of treating or preventing a disease or condition, comprising:implanting into a subject one or more delivery articles, wherein a delivery article of the one or more delivery articles comprises a plurality of geometric elements, wherein the delivery article comprises a polymer and an active agent, wherein, when administered to a subject, the one or more delivery articles deliver the active agent to a target tissue or region.

2. The method of claim 1, wherein an amount of the active agent delivered to the target tissue or region is measured by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS / MS) or High-Performance Liquid Chromatography (HPLC).

3. A method of preferentially delivering an active agent to a target tissue or region of a subject to treat or prevent a disease or condition, comprising:implanting into the subject one or more delivery articles, wherein a delivery article of the one or more delivery articles comprises a plurality of geometric elements, wherein the delivery article comprises a polymer and an active agent, wherein a concentration of the active agent is higher in the target tissue or region than a non-targeted tissue or region.

4. The method of claim 3, wherein the concentration of the active agent is measured by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS / MS) or High-Performance Liquid Chromatography (HPLC).

5. The method of claim 3 or 4, wherein the concentration of the active agent is at least 2-fold, at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, at least 100-fold, at least 200-fold, or at least 500-fold higher in the target tissue or region than in the non-target tissue or region.

6. The method of any one of claims 3-5, wherein the non-target tissue or region is liver or blood vessel.

7. The method of any one of the preceding claims, wherein the target tissue comprises colorectal site, peritoneal site, or mesentery site.

8. The method of claim 7, wherein the target tissue comprises the colorectal site, optionally wherein the colorectal site comprises intraluminal site or serosa of bowel.

9. The method of claim 7, wherein the target tissue comprises the peritoneal site, optionally wherein the peritoneal site comprises peritoneal wall, left peritoneal cavity, or right peritoneal cavity.

10. The method of claim 7, wherein the target tissue comprises the mesentery site.WSGR Docket No. 56745-707.60111. The method of any one of the preceding claims, wherein the disease or condition is cancer or tumor.

12. The method of any one of the preceding claims, wherein the implanting comprises implanting the one or more delivery articles into or adjacent to the target tissue of the subject.

13. The method of any one of the preceding claims, wherein the implanting comprises implanting at least a first delivery article and a second delivery article into the subject.

14. The method of claim 13, wherein the first delivery article is coupled to the second delivery article.

15. The method of claim 13 or 14, wherein the first delivery article comprises a first plurality of geometric elements and the second delivery article comprises a second plurality of geometric elements.

16. The method of claim 15, wherein a first shape of the first plurality of geometric elements is coupled to a second shape of a second plurality of geometric elements.

17. The method of any one of the preceding claims, wherein the active agent is released locally at or near the site of implantation as determined by tissue bioanalysis.

18. The method of any one of the preceding claims, wherein the active agent is substantially not released to the systemic circulation as determined by plasma bioanalysis.

19. The method of any one of the preceding claims, wherein the active agent is released locally with a level of 100 to 5000 nanograms per gram (ng / g), compared to a level in the blood vessel or plasma therein below 15 nanograms per milliliters (ng / mL).

20. The method of any one of claims 1-19, wherein the subject received a therapy for the disease or the condition other than the drug delivery article prior to the implanting.

21. The method of any one of claims 1-19, wherein the therapy was received after the subject was diagnosed with the disease or the condition.

22. The method of any one of claims 1-19, wherein the subject has not responded to the therapy.

23. The method of any one of claims 1-19, wherein the subject experienced a morbidity of the disease or the condition after the therapy.

24. The method of any one of claims 20-23, wherein the therapy is surgery.

25. The method of any one of claims 20-23, wherein the therapy comprises systemic administration.

26. The method of any one of claims 20-23, wherein the therapy compriseschemotherapy.WSGR Docket No. 56745-707.60127. The method of any one of the preceding claims, wherein the disease comprises a cancer.

28. The method of any one of the preceding claims, wherein the one or more delivery articles is implanted adjacent to a tumor.

29. The method of any one of the preceding claims, wherein the one or more delivery articles is implanted at most 1 centimeter (cm) away from the tumor.

30. The method of any one of the preceding claims, wherein the drug delivery article is implanted over a tumor.

31. The method of claim 30, wherein at least a portion of the drug delivery article covers at least a portion of the tumor.

32. The method of any one of claims 28-31, wherein the tumor comprises a solid tumor.

33. The method of any one of claims 28-31, wherein the tumor comprises a colorectal tumor.

34. The method of claim 33, wherein the subject has been subjected to a total neoadjuvant therapy (TNT).

35. The method of any one of claims 28-31, wherein the tumor comprises a rectal tumor.

36. The method of any one of claims 28-31, wherein the tumor comprises an anal tumor.

37. The method of any one of claims 28-31, wherein the tumor comprises a lower gastrointestinal tract tumor.

38. The method of any one of claims 28-31, wherein the tumor comprises a pancreatic tumor.

39. The method of any one of claims 28-31, wherein the tumor comprises a lung tumor.

40. The method of any one of claims 28-31, wherein the tumor comprises a bone tumor.

41. The method of any one of the preceding claims, wherein the implanting comprises suturing the drug delivery article to a tissue of the subject.

42. The method of any one of the preceding claims, wherein the implanting comprises an endoscopic procedure.

43. The method of any one of the preceding claims, wherein the active agent comprises a therapeutic agent.

44. The method of any one of the preceding claims, wherein the active agent is substantially uniformly dispersed in a portion of the delivery article.

45. The method of any one of the preceding claims, wherein a geometric element of the plurality of geometric elements is formed by a porous border.WSGR Docket No. 56745-707.60146. The method of any one of the preceding claims, wherein a geometric element of the plurality of geometric elements is formed by a non-porous border.

47. The method of any one of the preceding claims, wherein a shape of a geometric element of the plurality of geometric elements is triangle, rectangle, square, diamond, pentagon, hexagon, polygon, circle, or oval.

48. A kit comprising:a container comprising the one or more delivery articles of any one of claims 1-47; andinstructions for use.

49. The kit of claim 48, further comprising another container comprising one or more tools configured to implant a delivery article to a subject.